MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  1 of 117  Template  18.0   
  
A Phase 2, Randomized, Double-blind, Placebo-controlled Study 
to Evaluate the Safety and Pharmacodynamic Effects of 
MEDI0382 in Obese Subjects With Non-alcoholic Fatty Liver 
Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH)  
Sponsor Protocol Number: D5671C00002  
 
 
Application Number: IND number: [ADDRESS_824395]: MEDI0382 (cotadutide)  
 
Sponsor: MedImmune Limited, a wholly owned subsidiary of 
[COMPANY_008], [COMPANY_003]  Cambridge, CB21 
6GH, [LOCATION_006]  
 
Medical Monitor:  [COMPANY_003]  
Medical Monitor, [COMPANY_008] 
Phone: [COMPANY_003]  
 
Protocol History, Date : Original Protocol, 15March2019  
Protocol Amendment 1, 17May2019 Protocol Amendment 2, 19Jul2019 Protocol Amendment 3, 19Aug2019 Protocol Amendment 4, 26Feb2020 Protocol Amendment 5, 20Apr2020 Protocol Amendment 6, 27Nov2020  
 
 
This document contains trade secrets and commercial information that is privileged or 
confidential and may not be disclosed without prior authorization from MedImmune.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  2 of 117  Template  18.0   
 PROTOCOL SYNOPSIS  
 
TITLE  
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic 
Effects of MEDI0382 in Obese Subjec ts With Non-alcoholic Fatty Live r Disease (NAFLD)/Non-alcoholic 
Steatohepatitis (NASH)  
HYPOTHESES  
Primary  Hypothesis:  
MEDI0382 will have an acceptable safe ty (including hepatic safety) and to lerability profile in subjects with 
NAFLD/NASH  
 
Secondary Hypothesis:  
Treatment with any one dose of MEDI0382 tested will lead  to a reduction in hepati c fat in subjects with 
NAFLD/NASH  
OBJECTIVES AND ENDPOINTS  
Type  Primary  Objective  Primary  Endpoint  
 
Safety  To assess the safety (including hepatic 
safety) and tolerability of MEDI0382 
compared with placebo  • Incidences of treatment emergent 
adverse events and serious adverse events through the end of the follow-up 
period.
 
Type  Secondary  Objectives  Secondary  Endpoints  
 
Pharmacodynamic 
effects  To assess the effect of MEDI0382 on 
relative and absolute change in hepatic 
fat as assessed by [CONTACT_619951]-proton density fat fraction (MRI-PDFF) compared with placebo
 • Percent change from baseline in hepatic fat fraction (HFF) at Week 19
 
• Absolute change from baseline to Week [ADDRESS_824396] of MEDI0382 on 
circulating mark ers of hepatic 
inflammation compared with placebo  Change and percent change from baseline to 
Week 19 in:  
• alanine aminotransferase (ALT)  
• aspartate aminotransferase (AST)  
• gamma glutamyl transferase (GGT)  
Pharmacodynamic 
effects  To assess the effect of MEDI0382 on 
body weight and body mass index 
(BMI) compared with placebo  • Change and percent change from 
baseline to Week 19 in body weight and 
BMI.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  3 of 117  Template  18.0   
  
 
Dose response  To assess the dose response of 
MEDI0382 on pharmacodynamic 
parameters  • HFF, body weight, safety, other 
imaging parameters, parameters of 
hepatic inflammation  
 
Immunogenicity   
To evaluate the immunogenicity of 
MEDI0382  • Development of anti-drug antibodies 
(ADA) and titer (if subjects are ADA positive) during treatment and
 
follow- up 
Type  Exploratory  Objectives  Exploratory  Endpoints  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
CONFIDENTIAL AND PROPRIETARY  4 of 117  Template  18.0   
 27Nov2020; Final  
 
 
  
 
  
 
  
 
 
STUDY  DESIGN  
This is a randomized, double-blind, place bo-controlled, study to evaluate the safety (including hepatic safety), 
tolerability and pharmacodynamic e ffects of two dose levels of ME DI0382 in obese subjects with 
NAFLD/NASH. The subjects will have biopsy-confirmed NAFLD/NASH with liver fibrosis stage F1, F2 or F3. 
Approximately 72 subjects will be ra ndomized across multiple study sites.  
Subjects will be recruited in parallel and randomized using a 2:1:2:1 ratio:  
• MEDI0382 300 μg – once daily subcutaneous (SC) doses of MEDI0382 300 μg (n = 24)  
• Placebo for MEDI0382 300 μg – matched placebo (n = 12).  
• MEDI0382 600 μg – once daily SC doses of MEDI0382 600 μg (n = 24)  
• Placebo for MEDI0382 600 μg – matched placebo (n = 12)  
Subjects will be in the study for approximately 27 week s (189 days), including a screening period of up to 
4 weeks, a 19-week treatment period, and a 4-week safety follow-up period.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824397] POPULATION  
Subjects will be aged ≥ 18 years with a body mass index ≥ 30 kg/m2, with biopsy-confirmed NAFLD/NASH, 
and liver fibrosis stage F1, F2 or F3.  
TREATMENT GROUPS AND REGIMENS  
• MEDI0382 300 μg: MEDI0382 SC 50 μg once daily for 1 week, followed by 100 μg daily for 2 weeks, 
200 μg daily for 2 weeks and 300 μg daily for 14 weeks (n = 24).  
• Placebo for MEDI0382 300 μg: matched placebo SC once daily for 19 weeks (n = 12).  
• MEDI0382 600 μg: MEDI0382 SC 50 μg once daily for 1 week, followed by 100 μg daily for 2 weeks, 
200 μg daily for 2 weeks, 300 μg daily for 2 weeks, 400 μg daily for 2 weeks, 500 μg daily for 2 weeks 
and 600 μg daily for 8 weeks (n = 24).  
Placebo for MEDI0382 600 μg: matched placebo SC once daily for 19 weeks (n = 12).  
STATISTICAL  METHODS  
Sample size: The primary objective of the stu dy is safety, but sample size and power are calculated on efficacy 
endpoint HFF. Assuming 20% treatment  difference on relative change in  HFF with standard deviation  
(SD) = 20%, and assuming a 25% dropout rate, 24 subjects  per group will provide about  83% power to detect a 
treatment difference between a MEDI 0382 group and the placebo (alpha = 0.05, 2-sided). No multiplicity 
adjustment for alpha is planned.  
Statistical analyses: The safety analyses will be based on the As-treated population.  Treatment emergent 
adverse events will be summarized for incidence with number and percentage. Other safety data, such as vital signs, clinical laboratory data, and dECG will be summarized descriptively.
 
The pharmacodynamic analyses will be based on the Inte nt-to-treat population. For pharmacodynamic endpoints 
with continuous distribution, analys is of covariance (ANCOVA) adjusted for baseline value will be conducted. 
Pharmacokinetic and immunogenicity analyses: Pharmacokinetic parameters such as, but not limited to, C max, 
tmax, and AUC per group on the last day of  dosing, may be estimated from pl asma concentration-time data for 
MEDI0382 if data permit. Descriptiv e statistics will be generated fo r pharmacokinetic parameters for 
MEDI0382 in group. Additional summar y statistics on predose concentr ations and specific postdose 
concentrations may be derived, if data permits, from all groups. Subject s who have at least one measurable 
concentration time point of investigational product will be used for this analysis. Samples confirmed positive for 
ADA will be analyzed for antibody titer, ADA in cidence rate and titer will be tabulated.  
Interim analysis: An interim analysis is planned after approxim ately [ADDRESS_824398] completed approximately 
19 weeks of treatment. The purpose of th is interim analysis is to help in form further clinical development; no 
changes will be made to this study unless a safety signal is observed. The interim an alysis results will not be 
provided to the investigator. The interim analysis will be described in the interim analysis charter.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824399] OF ABBREVIATIONS.................................................................................................... 11  
1 INTRODUCTI ON .................................................................................................. 14  
1.1 Disease Background ............................................................................................... 14  
1.2 MEDI0382 Background  .......................................................................................... 15  
1.3 Summary of Nonclinical Experience  ...................................................................... 15  
1.4 Summary of Clinical Experience ........................................................................... 16  
1.5 Rationale for Conducting the Study ....................................................................... 17  
1.6 Benefit-risk and Ethical Assessment ...................................................................... 18  
1.7 Research Hypotheses .............................................................................................. 18  
1.7.1 Primary Hypothesis ................................................................................................ 18  
1.7.2 Secondary Hypotheses  ............................................................................................. 19  
2 OBJECTIVES AND ENDPOINTS ....................................................................... 19  
2.1 Primary Objective and Associated Endpoint ......................................................... 19  
2.2 Secondary Objectives and Associated E ndpoints .................................................. 20  
2.3 Exploratory Objectives and Associated Endpoints ................................................ 21  
3 STUDY DESIGN ................................................................................................... 22  
3.1 Description of the Study ........................................................................................ 22  
3.1.1 Overview ................................................................................................................ 22  
3.1.2 Treatment Regimen ................................................................................................ 24 
3.1.3 Management of Study Medication Related Toxicities ........................................... 25  
[IP_ADDRESS]  Tolerability ............................................................................................................. 25  
[IP_ADDRESS]  Hypoglycemia ......................................................................................................... 25  
[IP_ADDRESS]  Persistent Hyperglycemia ....................................................................................... 26  
3.2 Rationale for Dose, Population, and E ndpoints ...................................................... 26  
3.2.1 Dose Rationale ....................................................................................................... 26  
3.2.2 Rationale for Study P opulation .............................................................................. 28  
3.2.3 Rationale for Endpoint(s) ....................................................................................... [ADDRESS_824400] ............................................................ 34  
4.1.8 Study Stoppi[INVESTIGATOR_2121] .......................................................................................... 35  
4.1.9 Replacement of Subjects ........................................................................................ 36  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  7 of 117  Template  18.0   
 4.1.10  Withdrawal of Informed Consent for Data and Biological Samples ..................... 36  
4.2 Schedule of Study Procedures  ................................................................................. 37  
4.2.1 Enrollment/Screening Period ................................................................................. 37  
4.2.2 Randomized Treatme nt Period ............................................................................... 40  
4.2.3 Follow-up Period .................................................................................................... 53  
4.3 Description of Study Procedures ............................................................................ 54  
4.3.1 Efficacy................................................................................................................... 54  
4.3.2 Safety ...................................................................................................................... 5 4 
[IP_ADDRESS]  Medical History ...................................................................................................... 54  
[IP_ADDRESS]  Physical Examination ............................................................................................. 55 
[IP_ADDRESS]  Digital Electrocardiogram....................................................................................... 55  
[IP_ADDRESS]  Vital Signs .............................................................................................................. 56  
[IP_ADDRESS]  Weight, Height, BMI, Waist and Hip Circumference ............................................ 57  
4.3.3 Patient Reported Outcomes .................................................................................... 58  
[IP_ADDRESS]  Administration of Patient-Reported Outcome ....................................................... [ADDRESS_824401] Food Intake / Dosing Diary Completion ................................................... 58  
4.3.5 Pharmacodynamic Evaluation and Methods .......................................................... 59  
[IP_ADDRESS]  Magnetic Resonance Imaging (Including MRI- PDFF)  .......................................... 59  
[IP_ADDRESS]  Fibroscan ................................................................................................................ [ADDRESS_824402](s) ..................................................................... 63  
[IP_ADDRESS]  Investigational Product Handling  ............................................................................ 64  
[IP_ADDRESS]  Investigational Product Inspection ......................................................................... 64  
[IP_ADDRESS]  Dose Preparation Steps .......................................................................................... 65  
[IP_ADDRESS]  Treatment Administration ...................................................................................... 66  
[IP_ADDRESS]  Monitoring of Dose Administration ....................................................................... 67  
[IP_ADDRESS]  Reporting Product Complaints ............................................................................... 67  
4.5.2 Additional Study Medications ................................................................................ 68  
4.5.3 Labeling .................................................................................................................. 68  
4.5.4 Storage .................................................................................................................... 68  
4.5.5 Treatment Compliance  ............................................................................................ 68  
4.5.6 Accountability ......................................................................................................... 68  
4.6 Treatment Assignment and Blinding ...................................................................... 69  
4.6.1 Methods for Assigning Treatment Groups ............................................................. 69  
4.6.2 Methods to Ensure Blinding  ................................................................................... 69  
4.6.3 Methods for Unblinding ......................................................................................... 69  
[IP_ADDRESS]  Unblinding in the Event of a Medical Emergency ................................................. 69  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  8 of 117  Template  18.0   
 [IP_ADDRESS]  Unblinding for Interim Analysis Purposes ............................................................. 70  
4.7 Restrictions During the Study and Concomitant Treatment(s) .............................. 70  
4.7.1 Permitted Concomitant Medications ...................................................................... 70  
4.7.2 Prohibited Concomitant Medications ..................................................................... 71  
4.8 Statistical Evaluation .............................................................................................. 72  
4.8.1 General Considerations........................................................................................... 72  
4.8.2 Sample Size ............................................................................................................ 72  
4.8.3 Efficacy................................................................................................................... 72  
[IP_ADDRESS]  Efficacy Analysis .................................................................................................... 72  
[IP_ADDRESS]  Additional Analyses of  the Efficacy  Endpoint ....................................................... 73  
4.8.4 Safety ...................................................................................................................... 7 3 
[IP_ADDRESS]  Analysis of Adverse Events ................................................................................... 73  
[IP_ADDRESS]  Analysis of Clinical Laboratory Parameters .......................................................... 74  
4.8.5 Analysis of Immunogenicity/Pharmacokinetics ...................................................... 74  
4.8.6 Interim Analysis ..................................................................................................... 74  
5 ASSESSMENT OF SAFETY ................................................................................ 75  
5.1 Definition of Adverse Events  ................................................................................. 75  
5.2 Definition of Serious Adverse Events .................................................................... 75  
5.3 Recording of Adverse Events ................................................................................ 75  
5.3.1 Time Period for Collection of Adverse Events ...................................................... 76  
5.3.2 Follow-up of Unresolved Adverse Events ............................................................. 76  
5.3.3 Deaths ..................................................................................................................... 76  
5.3.4 Adverse Events Based on Signs and Symptoms .................................................... 76  
5.3.5 Adverse Events Based on Examination and Tests ................................................. 76  
5.3.6 Potential Hy’s Law and Hy’s Law ......................................................................... 77  
5.4 Reporting of Serious Adverse Events .................................................................... 77  
5.5 Other Events Requiring Immediate Reporting ....................................................... 78  
5.5.1 Overdose ................................................................................................................. 78  
5.5.2 Pregnancy ............................................................................................................... 78  
[IP_ADDRESS]  Maternal Exposure .................................................................................................. [ADDRESS_824403] Data Protection .......................................................................................... 82  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824404] OF TABLES  
Table 1 Primary Objective and Associated Endpoint ................................................ 19  
Table 2 Secondary Objectives and Associated E ndpoints ......................................... 20  
Table 3 Exploratory Objectives and Associated Endpoints ....................................... 21  
Table 4 Proposed Study Doses and Predicted Safety Margins Based on Safety  
Data From the Cynomolgus M onkey ........................................................... 28  
Table 5 Screening Schedule of Procedures ............................................................... 38  
Table 6  MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of 
Procedures ..................................................................................................... 41  
Table 7  MEDI0382/Matched Placebo [ADDRESS_824405] OF APPENDICES  
Appendix A Contraception Guidance ............................................................................... 99  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  10 of 117  Template  18.0   
 Appendix B Adverse Event Definitions and Additional Safety Information ................. 100  
Appendix C National Institute of Allergy and Infectious Diseases and Food Allergy  
and Anaphylaxis Network Guidance for Anaphylaxis Dia gnosis .............. 104  
Appendix D Actions Required in Cases of Increases in Liver Biochemistry and 
Evaluation of Hy’s Law .............................................................................. [ADDRESS_824406] (AUDIT)  ...................................... [ADDRESS_824407] (AUDIT) - Scoring instructions. 117  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824408] identification number  
FAAN  Food Allergy and Anaphylaxis Network  
FIB-4 fibrosis-4 score  
FLI fatty liver index  
FSH follicle-stimulating hormone  
GCP  Good Clinical Practice  
GLP- 1 glucagon-like peptide-1  
GGT  gamma glutamyl transferase  
HbA1c  hemoglobin  A1c  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  12 of 117  Template  18.0   
  
Abbreviation or 
Specialized Term  Definition  
HDLc  high density lipoprotein cholesterol  
HFF hepatic fat fraction  
HIV human immunodeficiency virus  
IB Investigator’s  Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
INR international normalized ratio  
IRB Institutional Review Board  
IWRS  interactive web response system  
LDLc  low density lipoprotein cholesterol  
LS least squares  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI-PDFF  magnetic resonance imaging-proton density fat fraction  
NAFLD  non-alcoholic fatty liver disease  
NAS  NASH activity score  
NASH  non-alcoholic steatohepatitis  
NIAID  National Institute of Allergy and Infectious Diseases  
NFS NAFLD fibrosis score  
NOAEL  no-observed-adverse-effect-level  
PPAR-γ peroxisome proliferator-activated receptor gamma  
PRO  patient reported outcomes  
RR relative  risk 
SAE  serious adverse event  
SC subcutaneous  
SD standard  deviation  
SF-[ADDRESS_824409]  upper limit of normal  
URC  Unblinded Review Committee  
US FDA  [LOCATION_002] Food and Drug Administration  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  13 of 117  Template  18.0   
  
Abbreviation or 
Specialized Term  Definition  
[LOCATION_003]  [LOCATION_002] of America  
w/v weight per volume  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  14 of 117  Template  18.0   
 1 INTRODUCTION  
1.1 Disease Background  
Non-alcoholic steatohepatitis (NASH) is part of the spectrum of liver diseases known as 
non-alcoholic fatty liver disease (NAFLD), ra nging from simple steatosis or non-alcoholic 
fatty liver (NAFL) to NASH. NAFLD is the most common cause of chronic liver disease in  
western industrialized countries and has an estimated prevalence of approximately 6% to 35% 
worldwide ( Bellentani, 2017 ; Younossi et al, 2016 ). NASH is the progressive form of the 
disease with a prevalence of approximately 2% to 3% of the general population, which can lead to cirrhosis and its complications, hepato cellular carcinoma, and end-stage liver disease 
(Bellentani et al, 2010 ). NASH is expected to become the leading cause for liver 
transplantation over the next decade, and is an important etiology driving the burden of hepatocellular carcinoma ( Cholankeril et al, 2017 ; Pais et al, 2016 ; Wong et al, 2014 ). NASH 
is closely associated with metabolic risk factors including obesity, type 2 diabetes mellitus 
(T2DM), and dyslipi[INVESTIGATOR_035]. Of particular relevance, epi[INVESTIGATOR_619921]-morbid obesity and T2DM in approximately 80% and 45% of patients with NASH, respectively ( Younossi et al, 2016 ). Pathophysiologically, NASH is 
frequently associated with insulin resistance, leading to adipose tissue dysfunction and increased hepatic de novo lipogenesis (DNL). Therefore, it is believed that both increased adipose tissue lipolysis and hepatic DNL contribute to increased liver fat and formation of 
lipid metabolites causing lipotoxicity. Lipot oxicity, oxidative stress and mitochondrial 
dysfunction are believed to contribute to the ha llmarks of NASH including signs of cell death 
or hepatocyte ballooning, lobular or portal inflammation and ultimately in some patients, liver fibrosis ( Marra and Lotersztajn, 2013 ; Neuschwander-Tetri, 2017 ). 
NASH is defined histologically as the combin ation of hepatic steatosis, inflammation and 
hepatocyte ballooning. Approximately 25% to 35% of patients with NASH develop liver fibrosis ( Mishra and Younossi, 2012 ). The fibrosis stage (F1 to F4) is the most important 
prognostic factor in NASH correlating with liver-related outcomes and mortality ( Angulo et 
al, 2015 ; Dulai et al, 2017 ). A number of factors have been shown to increase the risk of liver 
fibrosis progression to cirrhosis including presence of comorbid T2DM, increasing age, 
hypertension, and high body mass index (BMI) ( Angulo, 2007 ). 
 
There are currently no licensed pharmacological therapi[INVESTIGATOR_110234], with lifestyle 
modifications being the mainstay of treatment. Many patients do not achieve or maintain dietary goals and weight loss. Consequently, th e development of new therapi[INVESTIGATOR_619922], particularly given the expected increasing burden of this 
disease in parallel with the rising global epi[INVESTIGATOR_619923] T2DM ( Estes et al, 2018 ). 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  15 of 117  Template  18.0   
 1.2 MEDI0382 Background  
MEDI0382 is briefly described below. A detailed description of the chemistry, pharmacology, 
efficacy, and safety of MEDI0382 is provided in the Investigator’s Brochure (IB) . 
 
Glucagon-like peptide-1 (GLP-1) receptor agonist s are established treatments for T2DM that 
improve glycemic control, delay gastric empt ying, and depress appetite leading to modest 
weight loss (typi[INVESTIGATOR_897] 4% to 5.4% placebo-subtracted weight loss at 1 year) ( Astrup et al, 
2012 ). The strong association of NASH with the metabolic syndrome, particularly obesity and 
T2DM, has led to the investigation of GLP-[ADDRESS_824410] liraglutide 1.8 mg (Victoza®) 
for 12 weeks showed increased insulin sens itivity and metabolic improvement such as 
decreased levels of circulating non-esterified fatty acids and markers of adipose inflammation (Armstrong et al, 2014 ). In the main 48-week LEAN study of 52 patients with NASH, 
treatment with liraglutide 1.8 mg led to histol ogical resolution of NASH in 9 (39%) patients 
who underwent end of treatment liver biopsy compared with 2 (9%) patients in the placebo 
group (4.3 relative risk [RR], 95% confidence interval [CI] 1.0, 17.7; p = 0.019) ( Armstrong 
et al, 2016 ). Fewer patients in the liraglutide group versus the placebo group (9% versus 36%, 
respectively) had progression to liver fibrosis (0.2 RR, 95% CI 0.1, 1.0; p = 0.04).  
MEDI0382 is an oxyntomodulin-like peptide with targeted GLP-1 and glucagon receptor 
activity that is under development for the treatment of overweight/obese patients with T2DM. The additional glucagon component has similar effects to GLP-1 on gastric emptying and appetite and has also been shown to promote increased energy expenditure ( Habegger et al, 
2013 ; Lynch et al, 2014 ). Oxyntomodulin, a naturally occurring peptide with GLP-[ADDRESS_824411] activity, has been shown to promote weight loss through effects 
on appetite and energy expenditure in obese humans ( Wynne et al, 2006 ). In addition,  
co-infusion of GLP-1 and glucagon has demons trated synergistic effects on reducing food 
intake and increasing energy expenditure in humans ( Cegla et al, 2014 ). In a rodent model of 
NASH, the synthetic GLP-[ADDRESS_824412] G49 has been shown to 
improve the histological features of NASH following a methionine and choline-deficient diet (Valdecantos et al, 2017 ). 
MEDI0382, through targeted GLP-1 and glucagon receptor activity, is therefore hypothesized 
to lead to histological resolution of NASH, al ong with providing beneficial effects on glucose 
and lipid metabolism.  
 
1.3 Summary of Nonclinical Experience  
Refer to the current MEDI0382 IB for a complete summary of non-clinical information.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  16 of 117  Template  18.0   
 A series of repeat-dose-toxicity studies that included a 6-month study in rat and a 9-month 
study in the cynomolgus monkey were performed. Consistent with GLP-1 receptor  
mono-agonists, MEDI0382 exposure in both rats and cynomolgus monkeys resulted in the 
anticipated pharmacologic effects on body weight (reduced gain, or loss), food consumption (sporadic reductions), water consumption (l ow throughout dosing periods), gastric emptying 
(delayed in rats), liver (changes indicative of an effect on energy homeostasis in both species), pancreas (hypercellularity of the pancreatic islets, acinar degranulation), adrenal glands 
(increased prominence of the zona glomerulosa), and lungs (increased macrophage number, 
rats only). Skin findings (dry scaling, flaky and occasionally reddened) noted in-life in high dose group female cynomolgus monkeys only, appeared to be recovering in the treatment-free phase of the 9-month toxicology study. Microscopi[INVESTIGATOR_619924], hyperkeratosis and acanthosis in the affected females and in [ADDRESS_824413]-  and stress-related, with the secondary effects 
of MEDI0382-induced weight loss (greatest in females) potentially affecting skin condition in affected animals. MEDI0382 was not genotoxic and was not considered to be toxic to fertility or embryo fetal development in the rat and rabbit, with most findings generally being associated with maternal stress.  
In 2 mouse models of NASH, wild type (C57BL6J) or genetically obese ( Lep
ob/Lepob) mice 
fed a diet high in trans-fat, fructose, and cholesterol, had repeated subcutaneous (SC) once daily dosing of MEDI0382 (40 μg/kg or 111.84 μg/kg, respectively) for 6 weeks, that resulted 
in improvements in metabolism (reduced body weight, improved glucose tolerance), and liver 
enzymes, hepatic steatosis, and histological features of NASH compared with vehicle 
control(s). Both wild type and genetically obese mice treated with MEDI0382 had a statistically significant (p < 0.05) lower NASH activity score (NAS) compared with vehicle. The genetically obese mice treated with MEDI0382 had a statistically significant (p < 0.05) reduction in liver fibrosis compared with vehicle, which was supported by [CONTACT_486660] (p < 0.05) in plasma levels of the neoepi[INVESTIGATOR_619925] 9-mediated degraded type III collagen (C3M) and internal epi[INVESTIGATOR_619926] 7S domain of type IV 
collagen (P4NP7S) biomarkers (as measured by [CONTACT_619952]) compared with vehicle.  
1.[ADDRESS_824414] study with MEDI0382 in subjects with non-cirrhotic NAFLD/NASH with 
fibrosis stages F1, F2, or F3, however, seven clinical studies with MEDI0382 are complete 
and six ongoing including two studies with dosing up to 600 μg, one in obese subjects with 
T2DM and the other in subjects with chronic weight management or obesity (see current IB for details). Safety assessments for the completed studies show that the administration of  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  17 of 117  Template  18.0   
 MEDI0382 was generally well tolerated, with more frequent, usually mild or moderate, 
gastrointestinal treatment emergent adverse events as expected from this drug class.  
 
In the completed Phase 1/2a (Study D5670C00002) study conducted in 51 overweight and 
obese subjects with T2DM who received 41 da ys of placebo or MEDI0382 titrated up to a 
dose of 200 μg, a mean reduction from baseline in weight of -4.12% (90% CI -4.88, -3.36) 
was observed in MEDI0382-treated subjects versus -1.78% (90% CI -2.52, -1.03) in placebo, 
and a mean reduction from baseline in glucose area under curve for mixed meal test 4 hours 
(AUCMMT.4 h) of -32.78% (90% CI -36.98, -28.57) versus -10.16% (90% CI -14.10, -6.21)  
in placebo, p < 0.0001. The effects of MEDI0382 (at a dose of 200 μg, dose titrated from  
100 μg) on hepatic fat content as measured by [CONTACT_9252]-proton density fat 
fraction (MRI-PDFF), was measured as an exploratory endpoint in this study, and demonstrated a significant reduction versus placebo ([ Absolute : least squares [LS] mean 
change (90%CI): -5.98 (-7.67, -4.29) versus -3.17 (-4.68, -1.65), p = 0.017; Relative : LS mean  
change (90%CI): -39.12% (-49.11, -29.14) versus -19.51% (-28.49, -10.53), p = 0.006])  
(Ambery et al, 2018 ). 
 
1.5 Rationale for Conducting the Study  
It has been previously shown that GLP-1 mono-agonists reduce liver fat and improve 
histological features of NASH ( Armstrong et al, 2016 ; Petit et al, 2017 ). Given MEDI0382 
has additional effects on glucagon that could lead to both a reduction in weight and may additionally lead to direct hepatic effects, it is anticipated that MEDI0382 use will lead to reduction of liver fat, liver stiffness and circul ating markers of hepatocellular injury in this 
subject population. As outlined above, up to 6- week data demonstrating the safety and 
efficacy of MEDI0382 across numerous metabo lic endpoints in overweight and obese T2DM 
populations in clinical settings (Study D5670C00002) have been collected. MEDI0382 (at a dose of 200 μg) was associated with significant reductions in liver fat, as assessed by  
[CONTACT_9268]-PDFF after 41 days of treatment, in a subgroup within a Phase 1/2a study in overweight/obese subjects with T2DM (Study D5670C00002). However, we have no data on the effect of MEDI0382 on safety and measures of hepatic steatosis and inflammation in the 
target population of NAFLD/NASH with fibrosis (F1, F2, or F3). Furthermore, we have no 
data at doses greater than 200 μg in a population with NAFLD/NASH with fibrosis. Access to 
such data are necessary to support development and design of a longer term pi[INVESTIGATOR_619927], particularly  as outlined in the recently released draft 
guidance from the [LOCATION_002] Food and Drug Administration (US FDA) on non-cirrhotic NASH with fibrosis.  
This will be the first study to investigat e the effect of MEDI0382 in subjects with  
non-cirrhotic NAFLD/NASH with fibrosis (F1, F2 , or F3). This proof of concept study will 
evaluate the safety, tolerability and pharm acodynamics of MEDI0382 in obese subjects with  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  18 of 117  Template  18.0   
 biopsy-confirmed non-cirrhotic NAFLD/NASH with fibrosis, enabling us to define the short- 
term effects of MEDI0382 in the target population for this therapy. In turn, it is expected that data from the proposed study will support key considerations for safety, study design, dose 
selection, sample size estimation, development of  endpoints and even regulatory discussions 
to enable larger longer studies of MEDI0382 in a population with non-cirrhotic NAFLD/NASH with fibrosis.  
 
1.[ADDRESS_824415] their origin in the 
Declaration of Helsinki and are consistent with International Council for Harmonisation 
(ICH)/Good Clinical Practice (GCP), and applicable regulatory requirements.  
 
This is the first clinical study in which MEDI 0382 will be used in subjects with NASH and is 
expected to lead to improvement of NASH based on non-invasive parameters, along with significant weight reduction.  
 
Identified and potential risks for MEDI0382 are based on available published data for other 
GLP-1 receptor mono-agonists and glucagon recepto r mono-agonists, as well as clinical and 
non-clinical data for MEDI0382. Identified risk s/adverse drug reactions for MEDI0382 are 
nausea, vomiting, injection site reactions and increased heart rate. The current IB should be consulted for potential risks; for MEDI0382 these include, alterations in blood pressure (BP), QT-interval prolongation, anaphylactic-type reactions, skin rash, pancreatitis, pancreatic carcinoma, thyroid cancer, hypoglycemia (with sulfonylurea/insulin) and diabetic ketoacidosis 
(following insulin reduction). The study design aims to minimize potential risks to subjects 
participating in this study based on the proposed inclusion/exclusion criteria, safety monitoring, and up-titration dosing schedule. Additionally, subjects will be monitored throughout the study for signs, symptoms, and/or laboratory analyses suggestive of hepatic decompensation. Subjects with hepatic decompen sation will be excluded from participation in 
this study (Section 5.2) and will be treated immediately according to standard of care.  
Subjects will be given appropriate training in SC injection administration.  
 
More detailed information about the known and expected benefits and identified and potential 
risks and expected adverse events (AEs) of  MEDI0382 may be found in the current IB.  
 
1.[ADDRESS_824416] an acceptable safety (including hepatic safety) and tolerability profile in 
subjects with NAFLD/NASH.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  19 of 117  Template  18.0   
 1.7.2 Secondary Hypotheses  
Treatment with any one dose of MEDI0382 tested will lead to a reduction in hepatic fat in 
subjects with NAFLD/NASH.  
 
2 OBJECTIVES AND ENDPOINTS  
2.1 Primary Objective and Associated Endpoint  
Table 1 Primary Objective and Associated Endpoint  
 
Type  Objective  Endpoint  
 
Safety  To assess the safety (including hepatic 
safety) and tolerability of MEDI0382 compared with placebo
 • Incidences of treatment emergent adverse events and serious adverse 
events through the end of the follow- 
up period.
 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824417] of MEDI0382 on 
relative and absolute change in hepatic 
fat as assessed by [CONTACT_619951]-proton density fat fraction 
(MRI-PDFF) compared with placebo  • Percent change from baseline in 
hepatic fat fraction (HFF) at Week 19  
• Absolute change from baseline to 
Week [ADDRESS_824418] of MEDI0382 on 
circulating mark ers of hepatic 
inflammation compared with placebo  Change and percent change from baseline to 
Week 19 in:  
• alanine aminotransferase (ALT)  
• aspartate aminotransferase (AST)  
• gamma glutamyl transferase (GGT)  
Pharmacodynamic 
effects  To assess the effect of MEDI0382 on 
body weight and body mass index (BMI) 
compared with placebo  • Change and percent change from 
baseline to Week 19 in body weight 
and BMI.  
 
Dose response  To assess the dose response of MEDI0382 on pharmacodynamic 
parameters
 • HFF, body weight, safety, other 
imaging parameters, parameters of 
hepatic inflammation  
 
Immunogenicity   
To evaluate the immunogenicity of 
MEDI0382  • Development of anti-drug antibodies 
(ADA) and titer (if subjects are ADA positive) during treatment and
 
follow- up 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  21 of 117  Template  18.0   
 2.3 Exploratory Objectives and Associated Endpoints  
Table 3 Exploratory Objectives and Associated Endpoints  
 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  22 of 117  Template  18.0   
 Table 3 Exploratory Objectives and Associated Endpoints  
 
3 STUDY DESIGN  
3.1 Description of the Study  
3.1.1 Overview  
This is a randomized, double-blind, placebo-cont rolled study to evaluate the safety (including 
hepatic safety), tolerability and pharmacodynamic effects of two dose levels of MEDI0382 in 
obese subjects with NAFLD/NASH. The subj ects will have biopsy-confirmed NAFLD/NASH 
with liver fibrosis stages F1, F2 or F3. Approximately 72 subj ects will be randomized across 
multiple study sites.  
 
Subjects will be recruited in parallel and randomized using a 2:1:2:1 ratio:  
 
 MEDI0382 300 μg: MEDI0382 SC 50 μg once daily for 1 week, followed by 100 μg 
daily for 2 weeks, 200 μg daily for 2 weeks and 300 μg daily for 14 weeks (n = 24).  
 Placebo for MEDI0382 300 μg: matched placebo SC once daily for 19 weeks (n = 12).  
 MEDI0382 600 μg: MEDI0382 SC 50 μg once daily for 1 week, followed by 100 μg 
daily for 2 weeks, 200 μg daily for 2 weeks, 300 μg daily for 2 weeks, 400 μg daily for 
2 weeks, 500 μg daily for 2 weeks and 600 μg daily for 8 weeks (n = 24).  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  23 of 117  Template  18.0   
  Placebo for MEDI0382 600 μg: matched placebo SC once daily for 19 weeks (n = 12).  
 
 
Subjects will be in the study for approximately 27 weeks (189 days), including a screening 
period of up to 4 weeks, a 19-week treatment period, and a 4-week safety follow-up period (Figure 1 ). 
 
During the screening period, baseline circulati ng markers (alanine aminotransferase [ALT], 
aspartate aminotransferase [AST], gamma gl utamyl transferase [GGT]) will be obtained.  
Subjects will return to site for study procedures at regular intervals, including the collection of 
blood sampling for serum biomarkers and pharm acokinetics, and MRI (including MRI-PDFF) 
when applicable (refer to the schedule of study procedures).  
To help inform further clinical development, once approximately [ADDRESS_824419] completed 
approximately 19 weeks of treatment an interim analysis is planned. The interim analysis 
results will not be provided to the investigator. The interim analysis will be described in the 
interim analysis charter.  
 
Figure 1 Study Flow Diagram  
 
 
MRI = magnetic resonance imaging; PDFF = proton density fat fraction; R = randomization  
a Subjects with MRI (including MRI-PDFF) and fibroscan  assessments performed within 60 days prior to 
screening do not need to undergo these assessments.  

MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  24 of 117  Template  18.0   
 3.1.2 Treatment Regimen  
Subjects randomized to placebo will receive matched placebo for 19 weeks.  
 
Dose Up-titration Period  
 
During the dose up-titration period, subjects ra ndomized to receive MEDI0382 will titrate to 
the top dose in each group as follows:  
 
MEDI0382 300 μg (5 weeks)  
 
 50 μg for 1 week (7 days)  
 100 μg for 2 weeks (14 days)  
 200 μg for 2 weeks (14 days)  
 
MEDI0382 600 μg (11 weeks)  
 
 50 μg for 1 week (7 days)  
 100 μg for 2 weeks (14 days)  
 200 μg for 2 weeks (14 days)  
 300 μg for 2 week s (14 days)  
 400 μg for 2 weeks (14 days)  
 500 μg for 2 weeks (14 days)  
 
Subjects may travel to the site for daily visits during Week 1 or alternatively should be given 
the option to stay overnight locally, if this is more convenient.  
 
Maintenance Treatment Period  
 
During the maintenance treatment period, subjects randomized to receive MEDI0382 will 
titrate to the maintenance dose and continue with this dose to the end of the period:  
 
MEDI0382 300 μg 
 
 300 μg for 14 weeks  
 
MEDI0382 600 μg 
 
 600 μg for 8 weeks  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  25 of 117  Template  18.0   
 3.1.3 Management of Study Medic ation Related Toxicities  
[IP_ADDRESS]  Tolerability  
To help prevent the occurrence of nausea and vomiting, prior to receiving investigational 
product, subjects will be counselled about meal size and eating habits. This advice should be 
re-iterated should symptoms occur once investigational product is initiated. In the event that symptoms do not improve, subjects should be offered anti-emetic therapy in accordance with institutional and local practice guidelines as long as medications that are prokinetic agents 
such as domperidone or metoclopramide are avoided.  
MEDI0382 600 μg group only: in the event that a subject is unable to tolerate the 
investigational product following up-titration to [ADDRESS_824420] eight subjects 
receiving 600 μg drop out or down-titrate to 500 μg, due to inability to tolerate the 600 μg 
dose, the remaining subjects in MEDI0382 600 μg group will not be up-titrated beyond the 
500 μg dose level.  
Investigators should monitor subjects with vomiting for signs of hypovolemia. Subjects with 
impaired renal function could be extra sensitive to hypovolemia. Such subjects should be informed about the importance of adequate hydration in case of nausea and vomiting. These 
subjects should also undergo additional laboratory testing for potential creatinine increases, as 
appropriate.  
 
[IP_ADDRESS]  Hypoglycemia  
Spontaneous and clinically significant hypoglycemia has not been experienced in completed 
studies with MEDI0382 up to a dose of [ADDRESS_824421] symptoms of 
hypoglycemia (hunger, dizziness, shaking, sweating, etc) or feel unwell. Any blood glucose 
level < 3.0 mmol/L (54 mg/dL) is considered as clinically significant hypoglycemia regardless of symptoms or not and should be reported by [CONTACT_619953].  
 
In the event of a severe hypoglycemic epi[INVESTIGATOR_85712] a subject with T2DM taking oral antidiabetic 
agents, dose reduction of such medication should be considered. In the event that no dose reduction of oral anti-diabetic agents can be undertaken, the subject may be withdrawn from treatment following discussion by [CONTACT_619954]. Subjects should not be discontinued from treatment based on single epi[INVESTIGATOR_619928]. The assessment of a single fingerstick or local  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824422] 
discontinuation due to hypoglycemia.  
 
The definition of a severe hypoglycemic event is as follows:  
 
“Severe hypoglycemia is an event requiring assistance of another person to actively 
administer carbohydrates, glucagon, or take other corrective actions. Plasma glucose 
concentrations may not be available during an event, but neurological recovery following the 
return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration” ( Seaquist et al, 2013 ). 
 
[IP_ADDRESS]  Persistent Hyperglycemia  
Rescue therapy will be considered for a ny subject with pers istent hyperglycemia.  
Self-monitored plasma glucose or blood glucos e readings will be collected and reviewed by 
[CONTACT_093]. Rescue therapy with add-on insulin is the preferred option for rescue therapy, but additional drug classes are permitted. In addition, the dose of metformin may be increased. Any change in anti-diabetic medications must be recorded in the electronic case report form (eCRF). It is advisable to avoid dipeptidyl pe ptidase-4 inhibitor (DPP-4i)-based treatments for 
rescue therapy for hyperglycemia. In the event of a need for rescue therapy for hyperglycemia, alternative options should be considered. Rescue  therapy with any GLP-[ADDRESS_824423], or 
peroxisome proliferator-activated receptor gamma (PPAR- γ) agonist-based intervention is 
prohibited.  
3.[ADDRESS_824424] been pe rformed to date in subjects with non-cirrhotic 
NAFLD/NASH with fibrosis; however, MEDI038 2 has been studied in overweight/obese 
subjects with T2DM (Section 1.4). Given the pathophysiological overlap of subjects with 
T2DM and NASH (~80% of NASH patients are obese, and approximately 50% have T2DM [Younossi et al, 2016 ]), the data for subjects with T2DM are relevant for subjects with NASH.  
 
Reductions in weight have been shown to be related to histological changes in NASH and 
liver fibrosis ( Vilar-Gomez et al, 2015 ). Therefore, the effect of body weight change is 
particularly relevant, as it provides a link between the two indications with respect to dose 
response.  
 
Current experience with marketed GLP-[ADDRESS_824425] therapy may be associated  with greater durability of weight loss, and 
there is a known association between degree of weight loss and improvement in hepatic fat as  
well as histological features of NASH with fibrosis. Furthermore, data from a bariatric surgery 
study indicate that greater weight loss is associat ed with greater improvements in steatosis and  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824426] in part responsible for 
the anticipated improvements in NAFLD/NASH, it is important to establish whether near maximal GLP-1/glucagon dual agonism at higher doses up to and beyond those studied exhibits a pharmacodynamic profile that recapi[INVESTIGATOR_619929]-[ADDRESS_824427] on hepatic fat in patients with non-cirrhotic NAFLD/NASH with fibrosis. 
MEDI0382 at 200 μg (Study D5670C00002) was associated with significant reductions in 
liver fat and improvement in transaminase levels in a group of overweight/obese subjects with T2DM. Assessment of safety and tolerability of doses of MEDI0382 higher than 300 μg and 
up to 600 μg in an obese population is currently ongoing (Study D5672C00001). Taken 
together, the planned active doses for the current proposed study in subjects with non-cirrhotic NAFLD/NASH with fibrosis will include a 600- μg dose arm, determined as the maximal 
tolerated dose in Cohort 1 of the ongoing titration Study D5672C00001 in 12 obese subjects 
treated with MEDI0382 for maximum 2 weeks on stable dose. Review of preliminary safety 
data revealed no new safety concerns with the data supportive of the use of such doses in similar settings. Therefore, the current study propo ses to assess the effects of MEDI0382 at 
the 600 μg dose in a population with biopsy-confirmed non-cirrhotic NAFLD/NASH with 
fibrosis (F1, F2, F3) (with the opportunity to down-titrate to [ADDRESS_824428] 8 subjects (see Section 3.1.3 ). However, there remains a risk that 
doses higher than 300 μg may not be tolerated in this population. In order to mitigate such 
risk, and to be able to gain meaningful information from this critical study, evaluation of the 
effects of MEDI0382 at the 300 μg dose in a second group of subjects with non-cirrhotic 
NAFLD/NASH with fibrosis (F1, F2, or F3) w ill be performed. Considering the separation 
between the two dose levels in terms of pl asma exposure, such a strategy will also add 
considerable value for optimization of dose selection for planned pi[INVESTIGATOR_619930]0382 NASH program.  
The no-observed-adverse-effect-level (NOAEL) of 90 μg/kg/day was based on findings in the 
9-month, daily repeat-dose SC toxicology study in the cynomolgus monkey. These were 
considered to be consistent with pharmacology-mediated induction of weight loss/lower 
weight gain, reversible changes in the pancreas (acinar degranulation and hypercellularity of the pancreatic islets), and changes in energy utilization and associated metabolic stress (minor changes in blood chemistry parameters, lower thym us weights). Treatment was also associated 
with changes in the skin (dermal inflammation, acanthosis and hyperkeratosis) in 3 of  
6 female cynomolgus monkeys dosed.  
 
While the NOAEL determined in the rat 6-month, daily repeat-dose SC toxicology study  
(ie, 7.5 μg/kg/day) was lower than that in the cynomolgus monkey, this was driven primarily 
by [CONTACT_619955] (C-cell hype rplasia, adenoma, and carcinoma) that were 
considered, in this species, to be adverse. Th is is a known class effect with GLP-1 receptor 
agonists that is considered rodent specific and of unknown relevance to humans ( Center for  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  28 of 117  Template  18.0   
 Drug Evaluation and Research, 2005 ). Therefore, cynomolgus monkey, and the toxicity 
profile of MEDI0382 generated in that species, are the most appropriate non-clinical species to use for clinical risk assessment and the setting of safety margins.  
 
Table 4 illustrates the main proposed clinical dose periods and estimated safety margins over 
the predicted maximum observed concentration (C max) and AUC in humans for this repeat- 
dose study and the observed C max and AUC at the NOAEL in the 9-month repeat-dose toxicity 
study in cynomolgus monkeys. The steady state C max and AUC-based safety margins at the 
maximum proposed human dose of 600 μg after up-titration steps based on cynomolgus 
monkey NOAEL (90 μg/kg/day) are 12-fold and 8-fold, respectively, which indicates that the 
exposure is anticipated to be lower in humans to that determined in monkeys at the NOAEL.  
 
Table 4 Proposed Study Doses and Predicted Safety Margins Based on Safety 
Data From the Cynomolgus Monkey  
 
 
 
Human Dose ( μg) Predicted Median Human 
Exposure at steady state  Safety Margin Over Cynomolgus 
Monkey Exposure at NOAELa at 
Day 273  
AUC tau 
(ng•hr/mL)  Cmax 
(ng/mL)  AUC  Cmax 
50 51 3.4 82 119 
100 84 5.5 50 74 
200 160 10.6 26 38 
300 249 17 17 25 
600 498 33 8 12 
AUC = area under the concentration-time curve; BMI = body mass index; C max = maximum observed 
concentration; NOAEL = no-obser ved-adverse-effect level.  
Note: The information in this table is based on BMI of 35 kg/m2. 
a NOAEL = 90 μg/kg/day  
 
3.2.2 Rationale for Study Population  
Obese subjects with biopsy-confirmed non-cirrhotic  NAFLD/NASH with fibrosis and with or 
without T2DM, will be recruited, as such subjects would gain the most benefit from treatment with MEDI0382, rather than healthy subjects who would not see disease benefits. Subjects with non-cirrhotic NAFLD/NASH with fibrosis stage F1, F2 or F3 (inclusive) will be 
recruited. In order to ensure a balance of subjects with early and advanced fibrosis, the number of subjects with F1 fibrosis will be capped at 25% in the study. Subjects with F4 
fibrosis (cirrhosis) will not be included because  histological progression is less relevant in 
these subjects, where the therapeutic emphasis is more on the reduction of the physiological 
abnormalities (e.g., elevated portal pressure). Obese subjects are included because excess 
weight is associated with the development of NASH and MEDI0382 is expected to promote 
weight loss.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  29 of 117  Template  18.0   
 3.2.3 Rationale for Endpoint(s)  
Rationale for Primary Endpoint  
 
1 The current study will evaluate the overall safety (including hepatic safety) and 
tolerability in the setting of multiple dosing of MEDI0382 (up to 600 μg) in a population 
with biopsy-confirmed non-cirrhotic NAFLD/NASH with fibrosis.  
 
Rationale for Secondary Endpoints  
 
[ADDRESS_824429] been associated with a therapeutic response in the 
resolution of NASH. MRI-PDFF has been demons trated to be as sensitive as histology for 
detecting changes in whole liver fat content in natural history and therapeutic studies (Meisamy et al, 2011 ). Furthermore, MRI-PDFF is a non-invasive assessment with less 
risk to the subject and is less operator-dependent than other methodologies. A relative 
reduction of liver fat content by [CONTACT_2902] 29% has been shown to be associated with histologic improvements in NASH ( Patel et al, 2016 ). Use of the GLP-[ADDRESS_824430] MEDI0382 was associated with significant reductions in liver fat in a group of 
overweight/obese subjects with T2DM in the setting of a subgroup within a Phase 1/2a 
study (Study D5670C00002). Therefore, it is reasonable to propose and anticipate a 
clinically relevant and statistically significant reduction of hepatic fat measured by  
[CONTACT_9268]-PDFF in a population of biopsy-confir med non-cirrhotic NAFLD/NASH with 
fibrosis. However, the population proposed for the current study is expected to have an admixture of pathologic features of NAFLD, NASH, and fibrosis, with varying degrees of 
improvement in each of these pathophysiologic features and varying time courses for 
such improvement in response to MEDI0382. Since steatosis will be a part of the 
pathophysiologic pi[INVESTIGATOR_1103], but may not be the dominant pathologic feature, it is expected that we will observe a significant and clinically relevant change in HFF in the current study, but of a magnitude that may be less robust than in a population with steatosis 
alone. Furthermore, it is anticipated that prolonged treatment should lead to greater 
reductions in HFF in response to MEDI0382. Taken together, we anticipate a difference from placebo in the relative reduction from baseline in HFF in response to at least one dose of MEDI0382 tested in the current study. It is reasonable to propose that such a change in steatosis along with decreases in inflammation and NASH disease activity  
following prolonged treatment should position ME DI0382 as a viable treatment option for 
subjects with biopsy-confirmed non-cirrhotic NASH with fibrosis.  
2 Hepatic fat fraction: Improvements in hepatic steatosis have been associated with a 
therapeutic response in the resolution of NA SH. MRI-PDFF has been demonstrated to be 
as sensitive as histology for detecting changes in whole liver fat content in natural history 
and therapeutic studies ( Meisamy et al, 2011 ). Furthermore, MRI-PDFF is a non-invasive 
assessment with less risk to the subject and is less operator-dependent than other methodologies. A reduction of absolute liver fat content by [CONTACT_2669] 5% has been shown to be associated with histologic improvements in NASH ( Patel et al, 2016 ). Use of the  
GLP-[ADDRESS_824431] MEDI0382 was as sociated with significant reductions in 
liver fat in a group of overweight/obese subjects with T2DM in the setting of a subgroup 
within a Phase 1/2a study (Study D5670C00002). Therefore, it is reasonable to propose  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  30 of 117  Template  18.0   
 and anticipate a reduction of absolute hepatic fat measured by [CONTACT_9268]-PDFF in a population 
of biopsy-confirmed non-cirrhotic NAFLD/NASH with fibrosis.  
3 Markers of hepatic inflammation: Changes in circulating levels of transaminases such as 
ALT, AST, and GGT are considered in part to represent changes in hepatic inflammatory activity. The current study will measure changes in circulating levels of transaminases as 
indices of hepatic inflammation in a population with non-cirrhotic NASH with fibrosis.  
4 Body weight and BMI: Excess body weight is associated with the development of NASH. 
Cotadutide is expected to promote weight loss and a reduction in body weight is 
potentially an indicator of therapeutic response.  
 
 
4 MATERIALS AND METHODS  
4.1 Subjects  
4.1.1 Number of Subjects  
In total, 72 subjects are planned for inclusion in this study; 24 subjects will be randomized to 
each of the MEDI0382 groups (300 and 600 μg); and [ADDRESS_824432] meet all of the following criteria:  
 
1 Provision of informed consent (with the exception of consent for future genetic and 
non-genetic research) prior to performing any study-specific procedures, including 
screening evaluations.  
2 Subjects aged ≥ 18 years at the time of consent.  
3 BMI ≥ 30 kg/m2 at screening.  
4 Hemoglobin A1c (HbA1c) ≤ 9.5% (inclusive) at screening if T2DM present, managed by 
[CONTACT_619956]/or a stable dose of metformin, sodium-glucose co-transporter 2 (SGLT-2) 
inhibitors, sulphonylureas or acarbose (ie, no major dose adjustments in prior 3 months to screening).  
5 Definitive NAFLD/NASH with NAS ≥ 4 with ≥ 1 in each component (ie, steatosis, 
lobular inflammation and ballooning), as diagnosed by [CONTACT_492946] 6 months of screening with liver fibrosis stage F1, F2 or  F3. The number of subjects with F1 will be 
capped at 25% in the study.  
6 Evidence of hepatic steatosis or liver fat ( ≥ 10%) by [CONTACT_9268]-PDFF. Subjects with imaging 
performed within 60 days prior to screening do not need to repeat this assessment at Visit 2 (Day -10).  
7 Women of childbearing potential:  
(a) Who are sexually active with a non-sterilized male partner must have used at least 
one highly effective method of contraception (see Section Appendix A for definition 
of females of childbearing potential and for a description of highly effective methods  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  31 of 117  Template  18.0   
 of contraception) from screening, and must agree to continue using such precautions 
through to the end of the study. It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period.  
Cessation of contraception after this point should be discussed with a responsible 
physician. Periodic abstinence, the rhythm method, and the withdrawal method are 
not acceptable methods of contraception.  
(b) Must have a negative urine pregnancy test within [ADDRESS_824433]; and not be breastfeeding.  
 
4.1.[ADDRESS_824434]’s ability to participate or affect the interpretation of the results of the study.  
2 Liver disease of other etiologies (e.g., alc oholic steatohepatitis; drug-induced, viral, or 
autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; 
hemochromatosis; alpha 1 antitrypsin defici ency; Wilson’s disease) including positive 
results for hepatitis B surface antigen (HBsAg) or hepatitis C antibody tests (anti-HCV).  
3 History of cirrhosis and/or hepatic decompensation, including ascites, hepatic 
encephalopathy or variceal bleeding.  
4 Prior or planned liver transplantation.  
5 Alcohol consumption > 21 units of alcohol per week for males and > [ADDRESS_824435] (AUDIT) questionnaire at screening ( Appendix F and Appendix G ). 
7 A history of type 1 diabetes mellitus (T1DM), a history of diabetic ketoacidosis or current 
use of insulin-based therapi[INVESTIGATOR_014].  
[ADDRESS_824436] (including bariatric surgery) which may affect gastric emptying or could affect the interpretation of safety and tolerability data.  
9 Physician-diagnosed diabetic subjects with c linically significant gastroparesis (as judged 
by [CONTACT_093]) or those treated for gastroparesis within 6 months prior to screening.  
10 History of > [ADDRESS_824437] 6 months prior to screening or recent (within 
3 months of screening) use of drugs approved for weight loss (e.g., orlistat,  
bupropi[INVESTIGATOR_2394]/naltrexone, phentermine-topi[INVESTIGATOR_052], phentermine, lorcaserin), as well as those drugs used off-label.  
[ADDRESS_824438] 6 months or who are due to undergo these procedures at the time of screening.  
12 Severe congestive heart failure ([LOCATION_001] Heart Association Class IV).  
13 History of neoplastic disease within 5 years prior to screening, except for adequately 
treated basal cell, squamous cell skin cancer, or in situ cervical cancer.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824439] year.  
16 Recent (within 3 months of baseline biopsy) us e of therapi[INVESTIGATOR_619931] (e.g., systemic corticosteroids, methotrexate, tamoxifen, amiodarone, or long- term use of tetracyclines).  
17 Recent (within 3 months of baseline biopsy) use of obeticholic acid or other therapy 
under investigation for NASH.  
18 High dose vitamin E (> 400 IU) unless on a stable dose for at least 1 year prior to the 
baseline biopsy, and not initiated after the biopsy was taken.  
19 Recent (within 3 months of baseline biopsy) use of GLP-[ADDRESS_824440] 30 days or 5 half-lives of th e therapy (whichever is longer) at the time of 
screening. Any prior exposure to MEDI0382 is not permitted.  
21 Concurrent participation in another interventional study of any kind or repeat 
randomization in this study.  
22 Severe allergy/hypersensitivity to any of the proposed study treatments or excipi[INVESTIGATOR_840].  
23 Contra-indication to MRI: such as subjects with pacemakers, metallic cardiac valves, 
magnetic material such as surgical clips, implanted electronic infusion pumps or other conditions that would preclude proximity to a strong magnetic field; subjects with history of extreme claustrophobia or subject cannot fit inside the MR scanner cavity.  
24 History of acute pancreatitis or current chronic pancreatitis. Subjects with serum 
triglyceride concentrations above 1000 mg/dL (11 mmol/L) at screening, as this can precipi[INVESTIGATOR_619932].  
25 Abnormal laboratory values including any of the following:  
(a) AST or ALT > 5 × upper limit of normal (ULN).  
(b) Impaired renal function defined as estimated glomerular filtration rate (eGFR)  
≤ 30 mL/minute/1.73 m2 at screening (estimated according to chronic kidney disease 
epi[INVESTIGATOR_8261] [CKD-EPI]).  
(c) Albumin < 35 g/L.  
(d) International normalized ratio (INR) > 1.3.  
(e) Total Bilirubin (TBL) > 25 μmol/L in the absence of known Gilbert’s disease. 
(f) Platelets < 140-150,000/mm3. 
(g) Any other clinically significant abnormalities in clinical chemistry, hematology, or 
urinalysis results as judged by [CONTACT_093].  
26 Severely uncontrolled hypertension defined as systolic blood pressure ≥ 180 mmHg 
and/or diastolic blood pressure ≥ [ADDRESS_824441] 10 minutes at screening or randomization.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  33 of 117  Template  18.0   
 27 Basal calcitonin level > 50 ng/L at screening, or history/family history of medullary 
thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2).  
28 Hemoglobinopathy, hemolytic anemia, or chronic anemia (hemoglobin concentration  
< 11.5 g/dL [115 g/L] for male subjects or < 10. 5 g/dL [105 g/L] for female subjects) at 
screening, or any other condition known to interfere with interpretation of HbA1c 
measurements  
29 Any positive results for human immunodeficiency virus (HIV) infection.  
30 Any [COMPANY_008], MedImmune, or study site employee, or close relatives of any of the 
aforementioned employees.  
31 Females who are pregnant or lactating.  
 
Subjects may be re-screened once if the reason for screen failure was transient (including but 
not limited to study-supplied equipment failure or unforeseen personal events that mandate missed screening visits).  
 
4.1.[ADDRESS_824442] Enrollment and Randomization  
Study participation begins (ie, a subject is “enrolled”) once written informed consent is 
obtained. Once informed consent is obtained, a subject identification (E-code) number will be 
assigned by a central system (e.g., an interactive web response system, IWRS), and the 
screening evaluations may begin to assess study eligibility (inclusion/exclusion) criteria. The 
E-code will be used to identify the subject during the screening process and throughout study 
participation, if applicable.  
 
A master log of all consented subjects will be maintained at the site and will document all 
screening failures (ie, subjects who are consented but do not meet study eligibility criteria and 
are not randomized), including the reason(s) for screening failure.  
 
Subjects who fail to meet the inclusion/exclusion criteria (ie, screening failures) should not be 
randomized or receive investigational product.  
 
4.1.5 Screen Failures  
Screen failures are defined as subjects who signed the informed consent form (ICF) to 
participate in the clinical study but are not subsequently randomized into the study. A minimal set of screen failure information is required to ensure transparent reporting of screen failure subjects to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information 
includes demography, screen failure details, eligibility criteria, and any SAE.  
Individuals who do not meet the criteria for participation in this study (screen failure) may be 
rescreened one time if they fulfil the inclusion/exclusion criteria then. The subject should sign a new informed consent if rescreened. The same  E-code will be assigned for the rescreened 
subject.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824443] the reason for screen failure recorded in the eCRF.  
 
4.1.6 Withdrawal from the Study  
Subjects are free to withdraw their consent to participate in the study (investigational product 
and assessments) at any time, without prejudice to further treatment. Subjects who withdraw consent will be asked about the reason(s) a nd the presence of any adverse events (AEs).  
Subjects who are permanently discontinued fro m receiving investigational product will be 
recommended to continue the study and follow the original visit schedule without taking 
investigational product. If a subject discontinues from the investigational product, he or she should be asked, at the discretion of the treating physician, to return to the study site for the 
Early Discontinuation Visit (see Table 8 ). Where possible, the Early Discontinuation Visit 
should be within [ADDRESS_824444] to follow-up (see Section 4.1.7 ). 
Subjects attending an Early Discontinuation Visit should also be asked to return 28 days (±3 
days) from the last investigational product dose for follow-up assessments (see Table 8 ) unless 
they are unable or unwilling to return. If the subject continues in the study, after the Early Discontinuation Visit, the next visits should be  planned in accordance to the original visit 
schedule. However, only [ADDRESS_824445] withdraws from the study, then hi s/her enrollment/randomization code cannot be 
reused. Withdrawn subjects will not be replaced.  
 
Regardless of the reason for termination, all data available for the subject at the time of 
discontinuation of follow-up must be recorded in the eCRF. All reasons for discontinuation of 
the treatment must be documented.  
 
4.1.[ADDRESS_824446] in question:  
 
[ADDRESS_824447] to follow-up.  
3 An AE that, in the opi[INVESTIGATOR_12440], warrants discontinuation of 
further dosing.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824448] non-compliance that, in the opi[INVESTIGATOR_26335], warrants 
withdrawal (e.g., refusal to adhere to scheduled visits).  
[ADDRESS_824449].  
7 Liver function tests meeting any of the following criteria:  
(a) ALT and/or AST are > 3 × ULN and TBL > 2 × ULN  
(b) ALT and/or AST are > 5 × ULN for ≥ 4 consecutive days, at any time after the initial 
confirmatory result in subjects with normal baseline values.  
(c) ALT and/or AST > 8 × ULN  
(d) New onset jaundice that is not explained by [CONTACT_94279]’s irrespective of other liver 
biochemistries  
(e) Albumin < 28 g/L  
(f) INR > 2  
8 Acute viral hepatitis.  
9 Symptoms or signs of cirrhosis and/or he patic decompensation (e.g., ascites, variceal 
bleeding, hepatic encephalopathy).  
[ADDRESS_824450], he or she should be asked, at the discretion of the treating physician, to return to the study site for the Early Discontinuation Visit (see Table 8 ). Where possible, the Early Discontinuation Visit 
should be within [ADDRESS_824451] to follow-up. Subjects attending an Early 
Discontinuation Visit should also be asked to return 28 days (±3 days) from the last investigational product dose for follow-up assessments (see Table 8 ) unless they are unable or 
unwilling to return. If the subject continues in the study, after the Early Discontinuation Visit, 
the next visits should be planned in accordance to the original visit schedule. However, only [ADDRESS_824452] 3 MRIs performed 
during the treatment period.  
4.1.8 Study Stoppi[INVESTIGATOR_619933], in the judgement of MedImmune, study subjects are placed at 
undue risk because of clinically significant sa fety findings. The following criteria should be 
fulfilled:  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  36 of 117  Template  18.0   
  Meet individual stoppi[INVESTIGATOR_103414]  
 Are assessed as causally related to investigational product  
 Are not considered to be consistent with continuation of the study.  
 
For the individual subject, all data available for the subject at the time of discontinuation or 
follow up must be recorded in the eCRF regardless of the reason for termination. All reasons for discontinuation of treatment must be documented.  
 
In terminating the study, the sponsor will ensure that adequate consideration is given to the 
protection of the subjects’ interests.  
 
4.1.[ADDRESS_824453] withdraws consent to the use of donated biological samples, the samples will be 
disposed of/destroyed, and the action documented. If samples are already analyzed, MedImmune is not obliged to destroy the results of this research.  
 
As collection of the biological samples is an integral part of the study, then the subject is 
withdrawn from further study participation.  
 
The Principal Investigator:  
 
 Ensures subjects’ withdrawal of informed consent to the use of donated samples is 
notified immediately to MedImmune.  
 Ensures that biological samples from that subject, if stored at the study site, are 
immediately identified, disposed of/destroyed, and the action documented.  
 Ensures the organization(s) holding the samples is/are informed about the withdrawn 
consent immediately and that samples are disposed of/destroyed, the action documented, and the signed document returned to the study site.  
 Ensures that the subject and MedImmune are informed about the sample disposal.  
 
MedImmune ensures the organizations holding the samples is/are informed about the 
withdrawn consent immediately and that sample s are disposed of/destroyed and the action 
documented and returned to the study site.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  37 of 117  Template  18.0   
 4.2 Schedule of Study Procedures  
Whenever vital signs, 12-lead digital el ectrocardiogram (dECG), and blood draws are 
scheduled for the same nominal time, the blood draws should occur last. The timing of the first 2 assessments should be such that it allows the blood draw (e.g., pharmacokinetics blood 
sample) to occur at the proper nominal time.  
 
4.2.1 Enrollment/Screening Period  
Table 5 shows all procedures to be conducted at the screening visit.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 5  Screening Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  38 of 117  Template  18.0   
  
Study  Period  Screening  
Visit Number  V1 V2f 
Procedure/Study  Day  Day -28 to -11  Day -10 ± 3 days  
Written informed consent/assignment of E-code number  x  
Informed consent for future  genetic research samples 
(optional)  x  
Informed consent for future non-genetic research samples 
(optional)  x  
Verify eligibility criteria  x x 
CLDQ-NASH and SF-36  x  
Dispensation/completion of diary (food intake)  x x 
Medical history, including smoking and alcohol history  x  
Demographics  x  
Physical examination (full)a x  
Weightb, height and BMI calculation  x  
dECGc x  
Vital signsd (BP, pulse, body temperature, RR)  x  
ABPMe  x 
MRI (including MRI-PDFF)f  x 
Fibroscanf  x 
AUDIT  questionnaire  x  
Assessment of SAEs  x x 
Concomitant medications  x x 
SC injection training/demonstration/verify subject’s ability 
to self-injectg x  
Collect blood for:  
Serum chemistry  x  
Hematology  x  
Coagulation  parameters  x  
Circulating markers (ALT, AST, GGT)  x  
Calcitonin  x  
HbA1c  x  
Lipase and amylase  x  
TSH  x  
Serum  triglycerides  x  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 5  Screening Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  39 of 117  Template  18.0   
  
Study  Period  Screening  
Visit Number  V1 V2f 
Procedure/Study  Day  Day -28 to -11  Day -10 ± 3 days  
Virology: hepatitis B surface antigen, hepatitis C virus 
antibody; HIV-1 and HIV-2  x  
FSH (postmenopausal females only)h x  
ADA blood sample  x  
Collect urine for:  
Urinalysis  x  
Pregnancy  test x  
Drug and alcohol screeni x  
ABPM = ambulatory blood pressure monitoring; ADA = anti-drug antibody; AE = adverse event; 
ALT = alanine aminotransferase; AST = aspartate aminotransferase; AUDIT = Alcohol Use Disorder  
Identification Test; BMI = body mass index; BP = bl ood pressure; CLDQ-NASH = Chronic Liver Disease 
Questionnaire for non-alcoholic steat ohepatitis; dECG = digital electroc ardiogram; eCRF = electronic case 
report form; FSH = follicle-stimulating hormone; GGT = gamma glutamyl transferase; HbA1c = hemoglobin 
A1c; HIV = human immunodeficiency virus; MRI = magnetic resonance imag ing; MRI-PDFF = magnetic 
resonance imaging-proton density fat fraction; RR = respi[INVESTIGATOR_697]; SAE = serious adverse event;  
SC = subcutaneous; SF-36 = Short- Form-36; E-code = subject iden tification number; TSH = thyroid 
stimulating hormone; V = visit.  
a Only the screening physical examination will be a full examination. For all time points thereafter, only 
an abbreviated physical examination is required.  
b Body weight should be measured in the morning,  after the subject has toileted and removed bulky 
clothing, including shoes. Cali brated scales should be used.  
c A single dECG recording should be pe rformed after the subject has rested  in the supi[INVESTIGATOR_42428] [ADDRESS_824454] 10 minutes (rest period for dECG  will suffice). Two consecutive BP  readings should be taken at 
intervals of at least [ADDRESS_824455] will then wear the monitor/cuff for approxima tely 24 hours (including overnight 
at home) and will remove the device at  home at the end of the 24-hour period.  
f Subjects are required to fast for at least 8 hours overni ght prior to Visit 2; subjects are permitted to drink 
water during this period of  fasting. MRI-PDFF and fibroscan should be performed with the subject in a 
fasted state. Subjects with MR I (including MRI-PDFF) and fibrosca n assessments performed within [ADDRESS_824456]’s ability to administer a SC injection should be verified by [CONTACT_54215] a single SC injection 
using normal saline provided by [CONTACT_779]. Willingness to perform this  for the duration of the study 
should be discussed with the subject.  
h FSH should only be checked in female subjects who are post-menopausal and have no previous 
confirmatory laborator y FSH result available.  
i An alcohol breath test is an acce ptable alternative to an alcohol  urine test. If multiple tests are 
performed and conflicting re sults occur any positive re sult should be documented.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
CONFIDENTIAL AND PROPRIETARY  40 of 117  Template  18.0   
 4.2.2 Randomized Treatment Period  
Table 6 and Table 7 show all procedures to be conducted during the treatment period for 
MEDI0382/matched placebo 300 μg and MEDI0382/matched placebo 600 μg, respectively.  
 
During the Coronavirus Dise ase 19 (COVID-19) Pandemic:  
 
 If a subject is unable to attend clinic visits, and/or receive study intervention due to 
COVID-19, the site staff should keep in close contact [CONTACT_1155], preferably through telephone calls at the time of the scheduled visit, to maintain awareness of their  
status. Assessments that can be performed over the phone should be completed such as 
adverse events, study drug administration and/or concomitant medications and any 
additional safety information and recorded in the eCRF and any assessments not performed should be recorded as ‘not done’.  
  If a subject is not able to attend their scheduled D78 MRI due to COVID-[ADDRESS_824457] opportunity and within 7 days of the original D78 scheduled date. All other subsequent visits should follow the original schedule.  
 If a subject cannot attend their scheduled D133 visit due to COVID-19, every effort 
should be made to perform the visit within [ADDRESS_824458] 
opportunity and within 7 days of the original D133 scheduled date where local 
regulations/public health guidance permit.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 6  MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  41 of 117  Template  18.0   
  
 
Study  Period  Treatment  Period  
5-week Up-titration  14-week Maintenance  
Dose  50 μg 100 μg 200 μg 300 μg 
Visit Number  3 4 5 6 7 8 9 10 11 12 13 14 
Study  Week  1 1 2 4 6 8 10 12 14 16 18 19 
Procedure/Study  Day  D1 D2, 3,  
4, 5, 6,  
7 D8 D22 D36 D50 
(± 2 
days)  D64 
(± 2 
days)  D78 
(± 2 
days)  D92 
(± 2 
days)  D106 
(± 2 
days)  D120 
(± 2 
days)  D133  
Outpatient  visita x x x x x x x x x x x x 
Daily visits for dosingb  x           
Dispense glucose meterc x            
Verify eligibility criteriad x            
Verify subject’s ability to self-inject  x  x          
Verify subject fasted for 8 hours 
prior to visit  x       x    x 
Randomization  x            
Dose initiation or up-titration  x  x x x        
Physical examination (abbreviated)  x  x x x x x x x x x x 
Weighte and BMI calculation  x  x x x x x x x x x x 
Height  x            
Waist and hip circumference  x       x    x 
dECGf x  x x x    x x x x 
Vital signsg (BP, pulse, body 
temperature, RR)  x  x x x    x x x x 
MRI (including MRI-PDFF)h x       x    x 
Fibroscanh x       x    x 
Assessments of AEs/SAEs  x x x x x x x x x x x x 
Concomitant medications  x x x x x x x x x x x x 
Completion of diary (food intake / 
dosing)   
 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 6  MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  42 of 117  Template  18.0   
  
 
Study  Period  Treatment  Period  
5-week Up-titration  14-week Maintenance  
Dose  50 μg 100 μg 200 μg 300 μg 
Visit Number  3 4 5 6 7 8 9 10 11 12 13 14 
Study  Week  1 1 2 4 6 8 10 12 14 16 18 19 
Procedure/Study  Day  D1 D2, 3,  
4, 5, 6,  
7 D8 D22 D36 D50 
(± 2 
days)  D64 
(± 2 
days)  D78 
(± 2 
days)  D92 
(± 2 
days)  D106 
(± 2 
days)  D120 
(± 2 
days)  D133  
IP dispensation for at home 
self-injection    
x x x x x x x x x  
IP accountability     x x x x x x x x x 
Collect bloodi for:             
Serum chemistry  x    x   x    x 
Hematology  x    x   x    x 
Coagulation  parameters  x           x 
MEDI0382  pharmacokineticsj x  x x x x x x  x  x 
ADAk x  x  x   x  x  x 
Circulating markers (ALT, 
AST, GGT)  x    
x x x x x x x x 
TSH  x           x 
Lipase and amylase  x           x 
HbA1c  x       x    x 
Calcitonin  x           x 
Fasting lipid profilel x       x    x 
Free fatty acids, β-HB, 
aceto-acetate  x       
x    
x 
Plasma glucose, insulin, 
glucagon, C-peptide and GLP-1  x       
x    
x 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 6  MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  43 of 117  Template  18.0   
  
 
Study  Period  Treatment  Period  
5-week Up-titration  14-week Maintenance  
Dose  50 μg 100 μg 200 μg 300 μg 
Visit Number  3 4 5 6 7 8 9 10 11 12 13 14 
Study  Week  1 1 2 4 6 8 10 12 14 16 18 19 
Procedure/Study  Day  D1 D2, 3,  
4, 5, 6,  
7 D8 D22 D36 D50 
(± 2 
days)  D64 
(± 2 
days)  D78 
(± 2 
days)  D92 
(± 2 
days)  D106 
(± 2 
days)  D120 
(± 2 
days)  D133  
Serum markers of liver 
fibrosism x       
x    
x 
NIS4  x       x    x 
Amino acids panel  xn       x    x 
Adiponectin  x       x    x 
Lipi[INVESTIGATOR_1800]  x       x    x 
CK18 and ELF™  x       x    x 
HOMA-IR calculation  x       x    x 
Sample for future genetic 
testing (optional)  x            
Sample for future non-genetic 
testing (optional)  x       
x    
x 
Collect urine for:              
Urinalysis  x    x   x    x 
Pregnancy test  (females of 
childbearing potential only)  x    
x   
x  
x  
x 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 6  MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  44 of 117  Template  18.0   
  
 
Study  Period  Treatment  Period  
5-week Up-titration  14-week Maintenance  
Dose  50 μg 100 μg 200 μg 300 μg 
Visit Number  3 4 5 6 7 8 9 10 11 12 13 14 
Study  Week  1 1 2 4 6 8 10 12 14 16 18 19 
Procedure/Study  Day  D1 D2, 3,  
4, 5, 6,  
7 D8 D22 D36 D50 
(± 2 
days)  D64 
(± 2 
days)  D78 
(± 2 
days)  D92 
(± 2 
days)  D106 
(± 2 
days)  D120 
(± 2 
days)  D133  
ADA = anti-drug antibody; AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; β-HB = β-hydroxybutyrate; BMI = body 
mass index; BP = blood pressure; C3M = neoepi[INVESTIGATOR_619934] 9-mediated degraded type III collagen; C6M = neoepi[INVESTIGATOR_9230] o f matrix metallopeptidase 
2-mediated degraded type VI collage; CK18  = cytokeratin 18; D = day; dECG = digita l electrocardiogram; eCRF =electronic case re port form;  
ELF™ = enhanced liver fibrosis score; GGT = gamma glutamyl transferase;  GLP-1 = glucagon-like peptid e-1; HbA1c = hemoglobin A1c ; HDLc = high 
density lipoprotein cholesterol; HOMA-IR = Homeostatic model asses sment of insulin resistance; IP = investigational product; LD Lc = low density lipoprotein 
cholesterol; MRI-PDFF = magnetic re sonance imaging-proton density fa t fraction; NIS4 = non-invasive  diagnostic score 4; P4NP7S = internal epi[INVESTIGATOR_619926] 
7S domain of type IV collagen; Pro-C3 = re leased N-terminal propeptide of type III collagen; Pro-C5  = released C-terminal prope ptide of type V collagen;  
Pro-C6 = neoepi[INVESTIGATOR_619935] C-terminal of type VI collagen; RR = respi[INVESTIGATOR_697]; T2DM = type 2 diabetes mellitus; TSH = thyroid st imulating hormone; 
SAE = serious adverse event  
Unless stated otherwise, blood samples are to be taken in a fasted state.  
Whenever vital signs, dECGs, and blood draws are scheduled fo r the same nominal time, the blood draws should occur last.  
a Subjects are required to be do sed at the clinic for the [ADDRESS_824459] 8 hours overnight prior to  Visits 3 (Day 1), 10 (Day 78) and 14 (Day  133); subjects are pe rmitted to drink wa ter during this period of 
fasting. On days where subjects attend the clinic in a fasted state, blood and urine samples should be obtained prior to admini stration of IP.  
b Subjects are required to receive their doses  at the clinic on Days 1-7, as prepar ation of the MEDI0382/matched placebo [ADDRESS_824460] symptoms of hypogly cemia (hunger, dizziness , shaking, sweating , etc) or feel unwell.  
d Check screening laboratory results and inclusion/exclusion criteria.  
e  Body weight should be measured predose in the morning while the subject is fasted (where applicable) a nd prior to breakfast, after the subject has toileted 
and removed bulky clothing, including s hoes. Calibrated scales should be used.  
f  Triplicate dECG recording shoul d be collected predose (within 20 minutes) on Visits 3 (Day 1), 5 (Day 8), 6 (Day 22), 7 (Day 36), and 14 (Day 133). At 
other time points, a single dECG recording wi ll be collected predose (wit hin 20 minutes). dECGs may be  repeated per site’s loca l procedure. The dECG 
triplicate recording should be taken prior to the pharmacokinetic samples for MEDI0382.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 6  MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  45 of 117  Template  18.0   
  
 
Study  Period  Treatment  Period  
5-week Up-titration  14-week Maintenance  
Dose  50 μg 100 μg 200 μg 300 μg 
Visit Number  3 4 5 6 7 8 9 10 11 12 13 14 
Study  Week  1 1 2 4 6 8 10 12 14 16 18 19 
Procedure/Study  Day  D1 D2, 3,  
4, 5, 6,  
7 D8 D22 D36 D50 
(± 2 
days)  D64 
(± 2 
days)  D78 
(± 2 
days)  D92 
(± 2 
days)  D106 
(± 2 
days)  D120 
(± 2 
days)  D133  
g Vital signs schedule:  
 Visits 3 (Day 1), 5 (Day 8), 6 (Day 22), 7 (Day 36), and 14 (Day 133): predose (within  20 minutes) then 15, 30 and 60 minutes ( ± 5 minutes) and  
2 hours (± 10 minutes).  
 All other visits: predose (within 20 minutes).  
For the predose BP measurements, two consecutive BP readings should  be taken at intervals of at least 1 minute, and the average  recorded in the eCRF.  
h MRI (including MRI-PDFF) and fibroscan should be performed predose,  in the morning with the subjects in a fasted state. The tim ing of the MRI and 
fibroscan should be kept as consis tent as possible at each study visit where these assessm ents are required.  
i Blood collection to be drawn pre dose if assessment occurs on a dos ing day. Subjects should be in  a fasted stated for blood coll ection drawn on Visits 3 
(Day 1), 10 (Day 78) and 14 (Day 133). For ot her visits, subject should al so be in fasted state fo r blood collection, whenever possible.  
j MEDI0382 pharmacokinetic sampling schedule:  
 For Visit 3 (Day 1), Visit 5 (Day 8), Visit 6 (Day 22), Visit 7 (Day 36): pr edose and 6 hours (± 30 minutes) postdose  
 For Visit 8 (Day 50), Visit 9 (Day 64), Vis it 10 (Day 78) and Visit 12 (Day 106): predose  
 For Visit 14 (Day 133): predose and at 2, 4, 6, 8, 10, 24, 48, 96 hours (± 30 minutes) postdose. S ubjects will be given the opt ion to stay at the 
clinical study site or stay overnight locally, if this is more convenient.  
k ADA samples will be collected prior to administration of MEDI0382.  
l Lipid profile includes total cholesterol, LDLc, HDLc, and triglycerides.  
m Markers of liver fibrosis (for collagen turnover) include Pro-C3, Pro-C5, Pro-C6, C3M, C6M and P4NP7S.  
n Predose on Day 1.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 7  MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  46 of 117  Template  18.0   
  
Study  Period  Treatment  Period  
11-week Up-titration  8-week Maintenance  
Dose  50 μg 100 
μg 200 
μg 300 
μg 400 μg 500 μg 600 μg 
Visit Number  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Study  Week  1 1 2 4 6 8 10 12 14 16 18 19 
Procedure/Study  Day  D1 D2, 3,  
4, 5, 6,  
7 D8 D22 D36 D50 D51 D52 D64 D65 D66 D78 D79 D80 D92 (±  
2 days)  D106 
(± 2 
days)  D120 
(± 2 
days)  D133  
Outpatient  visita x x X x x x x x x x x x x x x x x x 
Daily visits for dosingb  x                 
Dispense glucose 
meterc x                  
Verify eligibility 
criteriad x                  
Verify subject’s ability 
to self-inject  x  
X                
Verify subject fasted for 8 hours prior to visit
  
x            
x       
x 
Randomization  x                  
Dose initiation or up- titration
 x  
X x x x   
x   
x       
Physical examination 
(abbreviated)  x  
X x x x   
x   
x   
x x x x 
Weighte and BMI 
calculation  x  
X x x x   
x   
x   
x x x x 
Height  x                  
Waist and hip 
circumference  x           
x      
x 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 7  MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  47 of 117  Template  18.0   
  
Study  Period  Treatment  Period  
11-week Up-titration  8-week Maintenance  
Dose  50 μg 100 
μg 200 
μg 300 
μg 400 μg 500 μg 600 μg 
Visit Number  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Study  Week  1 1 2 4 6 8 10 12 14 16 18 19 
Procedure/Study  Day  D1 D2, 3,  
4, 5, 6,  
7 D8 D22 D36 D50 D51 D52 D64 D65 D66 D78 D79 D80 D92 (±  
2 days)  D106 
(± 2 
days)  D120 
(± 2 
days)  D133  
dECGf x  X x x x   x   x   x x x x 
Vital signsg (BP, pulse, 
body temperature, RR)  x  
X x x x xh xh x xh xh x xh xh x x x x 
ABPMi      x   x   x      x 
MRI- PDFFj x           x      x 
Fibroscanj x           x      x 
Assessments of 
AEs/SAEs  x x X x x x x x x x x x x x x x x x 
Concomitant 
medications  x x X x x x x x x x x x x x x x x x 
Completion of diary 
(food intake / dosing)   
 
IP dispensation for at 
home self-injection    
X x x x   
x   
x   
x x x  
IP accountability     x x x   x   x   x x x x 
Collect bloodk for:                   
Serum chemistry  x    x x x x x x x x x x    x 
Hematology  x    x       x      x 
Coagulation 
parameters  x                 
x 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 7  MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  48 of 117  Template  18.0   
  
Study  Period  Treatment  Period  
11-week Up-titration  8-week Maintenance  
Dose  50 μg 100 
μg 200 
μg 300 
μg 400 μg 500 μg 600 μg 
Visit Number  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Study  Week  1 1 2 4 6 8 10 12 14 16 18 19 
Procedure/Study  Day  D1 D2, 3,  
4, 5, 6,  
7 D8 D22 D36 D50 D51 D52 D64 D65 D66 D78 D79 D80 D92 (±  
2 days)  D106 
(± 2 
days)  D120 
(± 2 
days)  D133  
MEDI0382  
pharmacokineticsl x  
X x x x   
x   
x    
x  
x 
ADAm x  X  x       x    x  x 
Circulating 
markers (ALT, AST, GGT)
  
x     
x  
x    
x    
x    
x  
x  
x  
x 
TSH  x                 x 
Lipase and 
amylase  x                 
x 
HbA1c  x           x      x 
Calcitonin  x                 x 
Fasting lipid profile
n x           
x      
x 
Free fatty acids, β- 
HB, aceto-acetate  x           
x      
x 
Plasma glucose, 
insulin, glucagon, 
c-peptide, and GLP-1
  
x      
x  
x  
x  
x  
x  
x  
x  
x  
x     
x 
Serum markers of liver fibrosis
o x           
x      
x 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 7  MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  49 of 117  Template  18.0   
  
Study  Period  Treatment  Period  
11-week Up-titration  8-week Maintenance  
Dose  50 μg 100 
μg 200 
μg 300 
μg 400 μg 500 μg 600 μg 
Visit Number  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Study  Week  1 1 2 4 6 8 10 12 14 16 18 19 
Procedure/Study  Day  D1 D2, 3,  
4, 5, 6,  
7 D8 D22 D36 D50 D51 D52 D64 D65 D66 D78 D79 D80 D92 (±  
2 days)  D106 
(± 2 
days)  D120 
(± 2 
days)  D133  
NIS4  x           x      x 
Amino acids panel  xp           x      x 
Adiponectin  x           x      x 
Lipi[INVESTIGATOR_1800]  x           x      x 
CK18 and ELF™  x           x      x 
HOMA- IR 
calculation  x           
x      
x 
Sample for future 
genetic testing 
(optional)   
x                  
Sample for future 
non-genetic testing 
(optional)   
x            
x       
x 
Collect urine for:                    
Urinalysis  x    x       x      x 
Pregnancy test 
(females of 
childbearing potential only)
  
x     
x        
x     
x   
x 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 7  MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  50 of 117  Template  18.0   
  
Study  Period  Treatment  Period  
11-week Up-titration  8-week Maintenance  
Dose  50 μg 100 
μg 200 
μg 300 
μg 400 μg 500 μg 600 μg 
Visit Number  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Study  Week  1 1 2 4 6 8 10 12 14 16 18 19 
Procedure/Study  Day  D1 D2, 3,  
4, 5, 6,  
7 D8 D22 D36 D50 D51 D52 D64 D65 D66 D78 D79 D80 D92 (±  
2 days)  D106 
(± 2 
days)  D120 
(± 2 
days)  D133  
ABPM = ambulatory blood pressure monitoring; ADA = anti-drug an tibody; AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase;  
β-HB = β-hydroxybutyrate; BMI = body mass index; BP = blood pressure; C3M = neoepit ope of metallopeptidase 9-me diated degraded type III  collagen; C6M = 
neoepi[INVESTIGATOR_619925] 2-mediated degraded type VI collage; CK18 = cytokeratin 18; D = day; dECG = digital elect rocardiogram; eCRF = electronic case 
report form; GGT = gamma glutamyl transferase; GL P-1 = glucagon-like peptide-1; ELF™ = enha nced liver fibrosis  score; HbA1c = h emoglobin A1c; HDLc = high 
density lipoprotein cholesterol; HOMA-IR = Homeostatic model asse ssment of insulin resistance; IP = investigational product; LD Lc = low density lipoprotein 
cholesterol; MRI-PDFF = magnetic re sonance imaging-proton density fat fraction; NI S4 = non-invasive diagnos tic score 4; P4NP7S = internal epi[INVESTIGATOR_619926] 7S domain 
of type IV collagen; Pro-C3 = released N-terminal propeptide of type III collagen; Pro-C5 = released C-terminal propeptide of t ype V collagen; Pro-C6 = neoepi[INVESTIGATOR_619935] C-
terminal of type VI collagen; RR = respi[INVESTIGATOR_697]; T2DM = type 2 diabetes mellitus; TSH = thyroid stimulating hormone; SAE = serious adverse event  
Unless stated otherwise, blood samples are to be taken in a fasted state.  
Whenever vital signs, dECGs, and blood draws are scheduled fo r the same nominal time, the blood draws should occur last.  
a Subjects are required to be do sed at the clinic for the [ADDRESS_824461] 8 hours overnight prior to Visits 3 (D ay 1), 14 (Day 78) and 20 (Day 133); subjec ts are permitted to drink water during t his period of fasting. On days where 
subjects attend the clinic in a fasted st ate, blood and urine samples should be obtaine d prior to administra tion of IP. Subject s are required to visit the clinic on two 
subsequent days following up-titr ation to the 400, 500 and 600 μg dose for safety monitoring; subjec ts may travel to the site for daily visits during this time or 
alternatively should be given the option to stay overnight locally if this is more convenient.  
b Subjects are required to receive their doses  at the clinic on Days 1-7, as prepar ation of the MEDI0382/matched placebo 50- μg dose necessitates dilution that must be 
performed by [CONTACT_6624]. Subjects may travel  to the site for daily visits during this  time or alternatively should be given the  option to stay overnight locally if this is 
more convenient.  
c A glucose meter and test strips should be provided to subjects with T2DM. The subj ects should be trained in its use and advised  to test their capi[INVESTIGATOR_619936] (hunge r, dizziness, shaking, sweating, etc) or feel  unwell.  
d Check screening labs and inclusion/exclusion criteria.  
e Body weight should be measured predose in the morning while the subject is fasted (whe re applicable) and prior to breakfast, af ter the subject has toileted and 
removed bulky clothing, including shoes.  Calibrated scales should be used.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 7  MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  51 of 117  Template  18.0   
  
Study  Period  Treatment  Period  
11-week Up-titration  8-week Maintenance  
Dose  50 μg 100 
μg 200 
μg 300 
μg 400 μg 500 μg 600 μg 
Visit Number  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Study  Week  1 1 2 4 6 8 10 12 14 16 18 19 
Procedure/Study  Day  D1 D2, 3,  
4, 5, 6,  
7 D8 D22 D36 D50 D51 D52 D64 D65 D66 D78 D79 D80 D92 (±  
2 days)  D106 
(± 2 
days)  D120 
(± 2 
days)  D133  
f Triplicate dECG recording should be collected predose (within 20 minutes) on Visits 3 (Day 1), 5 (Day 8), 6 (Day 22), 7 (Day 36 ), 8 (Day 50), 11 (Day 64), 14 (Day 
78), and 20 (Day 133). At other time points, a single dECG recording will be collected predose (within 20 minutes). dECGs may b e repeated per site’s local 
procedure. The dECG triplicate re cording should be taken prior to the pharmacokinetic samples of MEDI0382.  
g Vital signs schedule:  
 Visits 3 (Day 1), 5 (Day 8), 6 (Day 22), 7 (Day 36), 8 (Day 50), 11 (Day 64), 14 (Day 78), and 20 (Day 133): predose (within 20  minutes) then 15, 30 and  
60 minutes (± 5 minutes) and 2  hours (± 10 minutes).  
 All other visits: predose (within 20 minutes).  
For the predose BP measurement, two consecutive BP readings shoul d be taken at intervals of at least 1 minute, and the average recorded in the eCRF. On days 
when ABPM is due to be checked, a set of vital signs s hould be performed prior to a pplication of the ABPM cuff.  
h Orthostatic BP is to be taken predose at the timepoints specified above. Measurement of orthostatic BP changes will be performe d as follows:  
 After the subject has been supi[INVESTIGATOR_2525] a mini mum of 5 minutes, BP and puls e rate will be measured in duplicate (at least 1 minut e apart).  
 Immediately after supi[INVESTIGATOR_619937], a standing BP and pulse rate wi ll be measured in duplicate as follows:  
 First measurement: BP and pulse rate measur ed after at least 1 minute of standing.  
 Second measurement: BP and pulse rate measur ed after at least [ADDRESS_824462] wil l wear the monitor/cuff for 
approximately 24 hours (including ove rnight at home) and will remove the device at home at the end of the 24-hour period and re turn the monitor at their next visit.  
j MRI (including MRI-PDFF) and fibroscan should be performed predose in the morning with the subjects  in a fasted state. The timi ng of the MRI (including MRI- 
PDFF) and fibroscan should be kept as consistent as possible at each study vis it where these assessments are required.  
k Blood collection to be drawn pre dose if assessment occurs on a dos ing day. Subjects should be in  a fasted state for blood colle ction drawn on Visits 3 (Day 1), 14 
(Day 78) and 20 (Day 133). For other visits, subject should also  be in fasted state for blood collection, whenever possible.  
l MEDI0382 pharmacokinetic sampling schedule:  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020; Final  
Table 7  MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures  
CONFIDENTIAL AND PROPRIETARY  52 of 117  Template  18.0   
  
Study  Period  Treatment  Period  
11-week Up-titration  8-week Maintenance  
Dose  50 μg 100 
μg 200 
μg 300 
μg 400 μg 500 μg 600 μg 
Visit Number  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
Study  Week  1 1 2 4 6 8 10 12 14 16 18 19 
Procedure/Study  Day  D1 D2, 3,  
4, 5, 6,  
7 D8 D22 D36 D50 D51 D52 D64 D65 D66 D78 D79 D80 D92 (±  
2 days)  D106 
(± 2 
days)  D120 
(± 2 
days)  D133  
 For Visit 3 (Day 1), Visit 5 (Day 8), Vis it 6 (Day 22), Visit 7 (Day 36), Visit 8 (D ay 50), Visit 11 (Day 64), and Visit 14 (Da y 78): predose and 6 hours 
(± 30 minutes) postdose  
 For Visit 18 (Day 106) predose  
 For Visit 20 (Day 133): predose and at 2, 4, 6, 8, 10, 24, 48, 96 hours (± 30 minutes) postdose. S ubjects will be given the opt ion to stay at the clinical study 
site or stay overnight locally , if this is more convenient.  
m ADA samples will be collected prior to administration of MEDI0382.  
n Lipid profile includes total cholesterol, LDLc, HDLc, and triglycerides.  
o Markers of liver fibrosis (for collagen turnover) in clude Pro-C3, Pro-C5, Pro-C6, C3M, C6M, and P4NP7S.  
p Predose on Day 1.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  53 of 117  Template  18.0   
  
4.2.3 Follow-up Period  
Table 8 shows all procedures to be conducted during the follow-up period.  
 
Table 8 Schedule of Follow-up Procedures  
 
Study  Period  Follow-up Period/Early Discontinuatione 
Visit Number  Visit 15/21 (EoS)  
Study Week  23 
Procedure/Study  Day  D161 (± 3 days)  
Physical examination (abbreviated)  x 
Weight and BMI calculation  x 
dECG  x 
Vital signsa (BP, pulse, body temperature, RR)  x 
Assessment of AEs/SAEs  x 
Concomitant medications  x 
Completion (food intake) / collection of diary  x 
Collect blood for:  
Serum chemistry  x 
Hematology  x 
Coagulation  parameters  x 
HbA1c  x 
ADAb x 
Circulating markers (ALT, AST, GGT)  x 
Calcitoninc x 
Lipid profiled, free fatty acids, β-HB, 
aceto-acetate  x 
Collect urine for:  
Urinalysis  x 
Pregnancy test (females of childbearing 
potential only)  x 
For Early discontinuation visit, the following should be performed in addition to the abovee: 
IP accountability  x 
MRI- PDFFf x 
Fibroscan  x 
MEDI0382  pharmacokineticsg x 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  54 of 117  Template  18.0   
  
Table 8 Schedule of Follow-up Procedures  
 
Study  Period  Follow-up Period/Early Discontinuatione 
Visit Number  Visit 15/21 (EoS)  
Study Week  23 
Procedure/Study  Day  D161 (± 3 days)  
ADA = anti-drug antibody; AE = adverse event; ALT = alanine aminotransfe rase; AST = aspartate 
aminotransferase; β-HB = β-hydroxybutyrate; BMI = body mass index; BP = blood pressure; D = day; 
dECG = digital electrocardiog ram; EoS = end of study; GGT = gamma glutamyl transferase;  
HbA1c = hemoglobin A1c; HDLc = high-density lipopr otein cholesterol; LDLc = low-density lipoprotein 
cholesterol; MRI-PDFF = magnetic re sonance imaging-proton density fat fraction; RR = respi[INVESTIGATOR_697]; 
SAE = serious adverse event; ULN = upper limit of normal.  
a For BP measurements, two consecutive readings should be taken at interv als of at least [ADDRESS_824463] will be  asked to return to provide another sample at 
approximately 3 months after the end of study visit. If that sample is ADA positive, additional visit(s) 
approximately every 3 months should continue until a sample tests negative for ADA or return to 
baseline level.  
c Calcitonin need only be re-measured in subjects who had a level > ULN on Day 133.  
d Lipid profile include total cholesterol, LDLc, HDLc, and triglycerides.  
e Subjects are required to fast for at least 8 hours pr ior to the Early Disconti nuation Visit; subjects are 
permitted to drink water during this period of fasting. Subj ects should be asked to return within [ADDRESS_824464] dose,  where possible. Subjects should al so be asked to return 28 days 
(±3 days) from the last investigational product dose for follow-up assessments unless they are unable or 
unwilling to return.Subjects who di scontinue investigational product but  wish to continue with study 
assessments should first perform th e Early Discontinuation Visit and th en continue the assessments as 
described in Table [ADDRESS_824465] more than 3 MRIs performed within the study treatment 
period (following randomization).  
f  MRI (including MRI-PDFF)  and fibroscan should be performed predose in the morning with the subjects 
in a fasted state. Subjects who discontinue from investigational product but continue on the study should 
not have more than 3 MRIs performed within the study treatment period (following randomization).  
g  One pharmacokinetic sample should be taken at any time during the vis it, but should be as close to the 
ADA sample as possible.  
 
4.3 Description of Study Procedures  
4.3.1 Efficacy  
Changes in HFF will be assessed by [CONTACT_9268]-PDFF (Section [IP_ADDRESS] ). 
 
4.3.2 Safety  
[IP_ADDRESS]  Medical History  
Complete medical history will include history and current medical conditions, past or present 
cardiovascular disorders, respi[INVESTIGATOR_696], gastrointe stinal, renal, hepatic, neurological, endocrine, 
lymphatic, hematologic, immunologic, dermatol ogical, psychiatric, genitourinary, drug and 
surgical history, or any other diseases or disorders.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  55 of 117  Template  18.0   
  
Smoking and alcohol history will also be recorded.  
 
In addition, the subjects will be asked the following questions:  
 
 In the last [ADDRESS_824466] you ever been treated with high dose Vitamin E to manage 
NASH (or any other condition)?  
 Did your prescriber consider your response adequate or inadequate?  
 In the last [ADDRESS_824467] you ever been treated with pi[INVESTIGATOR_619938] (or any 
other condition)?  
 Did your prescriber consider your response adequate or inadequate?  
 When was the last time you tried weight loss and exercise?  
 Did you lose weight that time and have you been successful keepi[INVESTIGATOR_619939]?  
 
The AUDIT questionnaire ( Appendix F and Appendix G ) to assess alcohol use habits will be 
completed at screening only ( Table 5 ). The results will be used for determining subject 
eligibility (Section 4.1.3 ). 
 
[IP_ADDRESS]  Physical Examination  
The full physical examination includes an assessment of the following: general appearance 
including skin inspection, lymph nodes, thyroi d, musculoskeletal/extremities, cardiovascular 
system, lungs, abdomen, and reflexes.  
 
The abbreviated physical examination includes the following: skin, extremities, cardiovascular 
system, lungs, and abdomen.  
 
Physical examinations will be performed at the time points specified in the schedule of 
procedures ( Table 5 , Table 6 , Table 7 , and Table 8 ). Investigators should pay special attention 
to clinical signs related to previous serious  illnesses; new or worsening abnormalities may 
qualify as AEs (additional details are provided in Section 5). In addition, the injection site will 
be assessed.  
 
At study termination clinically significant abnormalities in physical examination findings at 
study termination must be followed up by [CONTACT_619957], until the underlying cause is diagnosed, or resolution occurs.  
 
[IP_ADDRESS]  Digital Electrocardiogram  
Digital ECGs will be recorded at the sites according to Table [ADDRESS_824468] 10 minutes before dECG recordings are 
conducted. Digital ECGs may be repeated per site’s local procedure. The dECGs will be interpreted by a qualified physician (the investigator or qualified designee) at the clinical 
study site. The investigator should date and sign the dECG tracing and record the clinical  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  56 of 117  Template  18.0   
  
significance of any abnormal result on the tracing. Digital ECG evaluation will be recorded in 
the eCRF.  
 
Paper copi[INVESTIGATOR_619940] a 
central archive. Digital copi[INVESTIGATOR_619941].  
 
The following variables will be reported: PR, QRS, QT, HR, QTcB and QTcF intervals. The 
investigator may add extra 12-lead dECG safety assessments if there are any abnormal 
findings or if the investigator considers it is required for any other safety reason.  
 
[IP_ADDRESS]  Vital Signs  
Vital sign measurements will be obtained at the visits specified in Table [ADDRESS_824469] administration (where applicable) and before blood drawing. BP, and pulse measurements will be a ssessed with a completely automated device. 
Manual techniques will be used only if an automated device is not available.  
 
Route of body temperature measurement will be according to local procedures but should be 
consistent throughout the study for an individual subject.  
Orthostatic hypotension is defined as a drop of 20 mmHg in systolic BP or a drop of  
10 mmHg in diastolic BP within 2 to 5 minutes of standing up, or if standing causes signs and 
symptoms.  
 
Measurement of postural BP changes will be performed as follows:  
 
 After the subject has been in the supi[INVESTIGATOR_19636] a minimum of 5 minutes, BP and 
pulse rate will be measured in duplicate (at least 1 minute apart).  
 Standing BP and pulse rate will be measured in duplicate as follows:  
 First measurement: BP and pulse rate measured after at least 1 minute of standing.  
 Second measurement: BP and pulse rate measured after at least 3 minutes of 
standing.  
 
On days where ambulatory blood pressure monitoring (ABPM) is due to be checked, a 
predose set of vital signs should be performed prior to application of the ABPM cuff. BP 
should be measured once with the arm at heart level with the subject supi[INVESTIGATOR_1919]  
10 minutes prior to the measurement and measurements performed using an adequate arm cuff 
size. For time points where dECG recording pr ecedes vital sign measurement, the 10-minute  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824470] will be advised to undergo normal daily activities while wearing the cuff, and he/she will be advised to avoid any strenuous form of 
activity, bathing or showering while wearing the cuff. The subject will be advised to remain 
still during a measurement with the arm relaxed at  heart level. The subject will also be given 
advice on how to wear the device during the day and at night while sleepi[INVESTIGATOR_007], and what to expect in terms of frequency of readings during the day and overnight. During ABPM, systolic BP, diastolic BP, heart rate pressure, heart rate, and mean arterial pressure readings will be recorded over a period of 24 hours.  
[IP_ADDRESS]  Weight, Height, BMI, Waist and Hip Circumference  
Height and body weight will be measured at the time points specified in Table [ADDRESS_824471]  
[BMI = weight/(height)2], where weight is measured in kg, and height in meters). The height 
measurement recorded at screening will be used to calculate BMI for the eligibility assessment. The height measurement recorded at Visit 3 (Day 1) will be used for each 
subsequent BMI calculation.  
 
Waist and hip circumference will be measured at  the time points specified in the schedules of 
procedures ( Table 5 , Table 6 , Table 7 , and Table 8 ). The correct position for measuring waist 
circumference is midway between the uppermost border of the iliac crest and the lower border of the costal margin. A measuring tape of adequate length should be placed around the abdomen at the level of this midway point and a reading taken when the tape is snug but does not compress the skin, and at the end of a normal respi[INVESTIGATOR_149770]. Hip circumference should be measured around the widest portion of the buttocks, with the tape parallel to the 
floor. Waist-hip ratio is calculated as waist measurement divided by [CONTACT_619958] (ie, 
waist ÷ hip). For both measurements, the subject should stand with feet close together, arms at the side and body weight evenly distributed. Each measurement should be repeated twice; if the measurements are within 1 cm of one another, the average should be calculated. If the difference between the 2 measurements exceeds 1 cm, the 2 measurements should be repeated.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  58 of 117  Template  18.0   
 CCI  
 
 
 
  
 
  
 
  
 
  
 
  
 
 
 
  
  
 
  
 
  
 
  
 
 
 CCI 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  59 of 117  Template  18.0   
  
 
 
4.3.5 Pharmacodynamic Eval uation and Methods  
[IP_ADDRESS]  Magnetic Resonance Imaging (Including MRI-PDFF)  
MRI (including MRI-PDFF) will be performed, at the time points specified in Table 5 , 
Table 6 , Table 7 and Table 8 according to the Imaging Manual to assess HFF, CCI  
 
. Subjects with an MRI-PDFF assessment 
performed within 60 days prior to screening do not need to repeat this assessment at Visit 2 
(Day -10). If the screening MRI is determined to be of inadequate image quality by [CONTACT_619959]  
 
[IP_ADDRESS]  Fibroscan  
Fibroscan will be performed, at the time points specified in Table 5 , Table 6 , Table 7 and 
Table 8 to assess liver stiffness and attenuation parameters. Subjects with a fibroscan 
assessment performed within 60 days prior to screening do not need to repeat this assessment at Visit 2 (Day -10).  
 
4.3.[ADDRESS_824472] (dipstick). Abnormal laboratory results should be repeated as soon as possible (preferably within 24 to 48 hours).  
 
All clinical laboratory tests will be performed according to the timing and frequency presented 
in Table [ADDRESS_824473] be 
reported to the sponsor.  CCI 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  60 of 117  Template  18.0   
  
Information about how AEs based on laboratory tests should be recorded and reported are 
provided in Section 5. 
 
Additional safety samples may be collected if clinically indicated at the discretion of the 
investigator. The date, time of collection and results (values, units and reference ranges) will be recorded on the appropriate eCRF.  
 
The clinical chemistry, hematology, and urinalysis will be performed at a central laboratory.  
 
Serum chemistry  
• blood urea nitrogen  • calcium  
• creatinine  • glucose (fasting where required)  
• total protein  • sodium  
• albumin  • potassium  
• TBL  • chloride  
• alkaline phosphatase (ALP) • bicarbonate  
• ALT  • phosphorus  
• AST  • gamma glutamyl transferase  
Notes for serum chemistry  
Tests for AST, ALT, ALP, and TBL must be conducted concurre ntly and assessed concurrently.  
The additional collection time points for circul ating markers (ALT, AST, GGT) should be noted ( Table 5 , 
Table 6 , Table 7 , and Table 8 ). 
 
Hematology  
• red blood cell c ount • platelet  count  
• hemoglobin  • mean cell volume  
• hematocrit  • mean corpuscular hemoglobin concentration  
• absolute white blood cell count  • mean corpuscular hemoglobin  
• white blood cell count with percent differential  
 
Coagulation parameters  
• prothrombin time • thrombin  time  
• activated partial thromboplastin time • international normalized ratio  
 
Urinalysis  
• pH • ketones  
• specific  gravity  • protein  
• glucose  • microscopic analysis (if positive for blood, 
nitrites, or protein)  
• blood (urine hemoglobin/erythrocytes/blood) • bilirubin  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  61 of 117  Template  18.0   
 and GLP-1   
• color  • leukocytes  
• appearance  • urobilinogen  
• nitrites  
 
Females only  
• pregnancy test: urine human chorionic 
gonadotropin (hCG) (females of childbearing 
potential)   
 
• follicle stimulating hormone (FSH) (post- 
menopausal women only)  
 
Screening only  
• human immunodeficiency virus (HIV)-1 and 
HIV-2 antibodies  
• drug and alcohol screen   
 
• hepatitis B surface antigen (HBsAg) and 
hepatitis C antibody (anti-HCV)  
 
Additional laboratory assessments  
• calcitonin  • triglycerides  
• HbA1c  • amylase and lipase  
• thyroid stimulation hormone (TSH) • plasma glucose, insulin, glucagon, c-peptide,  
• total cholesterol  • free fatty acids  
• low-density lipoprotein cholesterol (LDLc) • beta- hydroxybutyrate  
• high-density lipoprotein cholesterol (HDLc), • aceto- acetate  
• amino acid panel • non-invasive diagnostic score 4 (NIS4)  
• collagen turnover (markers of liver fibrosis) • adiponectin: total and high molecular weight  
• lipi[INVESTIGATOR_1800]  • CK18  
• enhanced liver fibrosis (ELF™)  
 
4.3.7 Pharmacokinetic Evaluation and Methods  
Blood will be collected at predose and at specific postdose times to evaluate pharmacokinetics 
of MEDI0382 in plasma at the time points specified in Table 5 , Table 6 , Table 7 , and Table 8 . 
The pharmacokinetics of MEDI0382 in plasma will be measured utilizing a validated liquid 
chromatography-tandem mass spectrometry method (LC-MS/MS).  
 
4.3.8 Immunogenicity Evaluation and Methods  
Immunogenicity blood samples will be collected to evaluate ADA responses to MEDI0382. 
Anti-drug antibody sampling will occur by [CONTACT_619960](s) at the time points specified in Table [ADDRESS_824474] to MEDI0382. Titer evaluation and cross-reactivity to GLP-1 and glucagon may be performed  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  62 of 117  Template  18.0   
 CCI  
on samples that are confirmed positive for ADA.  Serum samples collected for ADA should be 
stored as described in the Laboratory Manual.  
 
Additional immunogenicity data will be reported in the clinical study report (CSR) or in an 
addendum, if applicable. Additional analyses may be conducted on anonymized, individual or pooled immunogenicity samples to further evaluate and validate the analytical method. Any 
results from such analyses may be reported separately from the CSR. Immunogenicity 
samples will be retained until point of license for this program and may be utilized for further characterization of the antibody response.  
 
4.3.[ADDRESS_824475]’s consent to participate in the genetic research components of the study is 
optional. See Appendix E or further information.  
 
4.3.[ADDRESS_824476]’s Last 
Visit, after which they will be destroyed.  
 
4.3.[ADDRESS_824477] over the entire course of 
their participation in the study is approximately 461 mL, plus an optional 60 mL for the MEDI0382 300 μg/matched placebo group and 557 mL, plus an optional 60 mL for the 
MEDI0382 600 μg/matched placebo group.  
 
4.4 Study or Study Component Suspension or Termination  
MedImmune reserves the right to temporarily suspend or permanently terminate this study or 
component of the study at any time. The reasons for temporarily suspending or permanently terminating the study may include but are not limited to the following:  
 
[ADDRESS_824478] to subjects  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824479] for this 
indication  
5 Sponsor decision to terminate the study based on a planned futility analysis  
 
If MedImmune determines that temporary suspension or permanent termination of the study 
or component of the study is required, MedImmune will discuss the reasons for taking such action with all participating investigators (or head of the medical institution, where 
applicable). When feasible, MedImmune will provide advance notice to all participating 
investigators (or head of the medical institution, where applicable) of the impending action.  
 
If the study or component of the study is suspended or terminated for safety reasons, 
MedImmune will promptly inform all investigator s, heads of the medical institutions (where 
applicable), and/or institutions conducting the study. MedImmune will also promptly inform 
the relevant regulatory authorities of the susp ension/termination along with the reasons for 
such action. Where required by [CONTACT_5279], the investigator or head of the medical institution must inform the Institutional Revi ew Board (IRB)/Independent Ethics Committee 
(IEC) promptly and provide the reason(s) for the suspension/termination. If the study or component of the study is suspended for safety reasons and it is deemed appropriate by [CONTACT_619961], approval from the relevant 
regulatory authorities (and IRBs/IECs when applicable) will be obtained prior to resuming the 
study.  
4.[ADDRESS_824480](s)  
MedImmune will provide the investigator(s) with investigational product ( Table 9 ) and diluent 
using designated distribution centers.  
 
Table [ADDRESS_824481]  Manufacturer  Concentration and Formulation as 
Supplied  
MEDI0382  MedImmune  2 mg/mL sterile liquid formulation, 1 mL 
nominal volume. Single dose vial.  
Matched  placebo  MedImmune  Sterile liquid formul ation buffer, 1 mL 
nominal volume. Single dose vial  
Note: Diluent solution (manufactured by [CONTACT_3211]) will be provided to sites. 
Note that the diluent solution is the same as the placebo.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824482] (nominal concentration of 2 mg/mL) in 
50 mM sodium phosphate buffer containing 1.85% weight per volume (w/v) propylene glycol, 
pH 7.8 intended for SC administration.  
 
Matched placebo is provided as a sterile solution of 50 mM sodium phosphate buffer 
containing 1.85% (w/v) propylene glycol, pH 7.[ADDRESS_824483] will be supplied to the site in blinded kits each containing 1 vial. Each 
kit has a unique number that is printed on all labels within the kit (ie, the outer carton label 
and the label on the vial within the carton). When investigational product is dispensed for  
at-home dosing, the site should transfer the required number of 1 vial kits into the supplied 
empty, double-blind labelled carton, which can hold up to 8 single vial kits.  
 
[IP_ADDRESS]  Investigational Product Handling 
In-clinic Investigational Product Handling  
Investigational product should be stored at 2°C to 8°C in the original container and should be 
protected from heat and light.  
 
Investigational products are supplied in single-use vials and do not contain preservatives, so 
after dose preparation any unused portion must be  discarded. Preparation of syringes for dose 
administration is to be performed using asep tic techniques. Total in-use storage time from 
needle puncture of the investigational product vial to start of administration should not exceed [ADDRESS_824484] a normal domestic refrigerator at home, which should be 
between 2°C and 8°C. Investigational product should be protected from heat and light.  
 
Subjects should be instructed not to store the investigational product directly adjacent to the 
refrigerator cooling element. Investigational product should not be used if it has been frozen.  
 
The subject should be instructed to remove from the refrigerator only the 1-vial kit required 
for their daily dose. All other kits are to be kept in the original carton in the refrigerator until required.  
 
[IP_ADDRESS]  Investigational Product Inspection  
Each vial selected for dose preparation should be inspected prior to use. The MEDI0382 or 
placebo solution in vials should not be cloudy, disc olored, or contain any visible particles. If 
there are any defects noted with the investigational product, the investigator and site monitor  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824485] Complaint section (Section [IP_ADDRESS] ) for 
further instructions.  
 
[IP_ADDRESS]  Dose Preparation Steps  
No incompatibilities between MEDI0382 and pl astics passing compatibility tests (ie, 
polyolefin or polyvinylchloride bags) have been observed.  
 
In-clinic Dose Preparation  
Investigational product is supplied in 3 mL glass vials at a nominal concentration of 2 mg/mL. 
The final delivery volume and concentration for each dose period and the syringe sizes to be 
used for preparation are described in Table [ADDRESS_824486] been observed 
between 2 mg/mL MEDI0382 stock solution and plastics passing compatibility tests (ie, polypropylene syringes). The diluted stock must be prepared and administered using 1 mL 
polypropylene syringes; the diluted stock is incompatible with 0.3 mL insulin syringes.  
 
For the MEDI0382/matched placebo [ADDRESS_824487] using a 1 mL syringe and 27 G needle and add it into a sterile empty vial. Using a new 1 mL syringe and 27 G needle, add 0.9 mL of diluent into the same vial. The vial should be mixed by [CONTACT_619962] a homogenous final admixture. Do not shake. The diluted dose should be administered using a 1.0 mL syringe (Table 10 ). Dilution and preparation of doses for administration is to be performed using 
aseptic techniques.  
Doses of 100 μg or greater do not require a dilution step and should be administered directly 
using a 0.3 mL insulin syringe.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  66 of 117  Template  18.0   
  
Table 10 MEDI0382 and Placebo Dose Preparation  
 
 
 
Dose Period  MEDI0382  
Concentration 
(mg/mL)  Volume of 
Injection (mL)  Syringe Size to be Used 
for Dose Administration  
(mL)  Number of 
Unitsa 
50 μg or placebob 0.2 0.25 1.0 NA 
100 μg or placebo  2.0 0.05 0.3 5 
200 μg or placebo  2.0 0.10 0.3 10 
300 μg or placebo  2.0 0.15 0.3 15 
400 μg or placebo  2.0 0.20 0.3 20 
500 μg or placebo  2.0 0.25 0.3 25 
600 μg or placebo  2.0 0.30 0.3 30 
NA = not applicable  
a The 0.3 mL insulin syringe is marked in ‘units’ where each unit = 0.01 mL, and 0.3 mL = 30 units.  
b For MEDI0382/matched placebo doses of 50 μg, a 10-fold diluted stock concentration of 0.2 mg/mL will be 
prepared by [CONTACT_619963], prior to administration.  
 
At-home Dose Preparation  
Only doses of [ADDRESS_824488] if the time outside of the refrigerator exceeds 4 hours; if storage time 
exceeds this limit, a new dose must be prepared from a new vial.  
 
[IP_ADDRESS]  Treatment Administration 
In-clinic Treatment Administration  
The first day of dosing is considered Day 1. On the day of each dose, investigational product 
will be administered according to the schedule of procedures, as soon as practical upon waking each morning prior to breakfast, ideally at the same time each day. Investigational 
product will be administered by [CONTACT_458765] s upervision as an SC injection in the lower 
abdomen using either a [ADDRESS_824489], ideally  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824490], and the sharps bin, at their next visit 
to the clinical site. All items can be returned at room temperature.  
 
[IP_ADDRESS]  Monitoring of Dose Administration 
Monitoring of In-clinic Dose Administration  
Injection sites should be routinely examined at  each study site visit. If any injection-site 
reaction meets the criteria for an AE (see Section 5), the event is to be reported on the AE 
eCRF, with the reaction described as specifically as possible.  
 
As with any biologic product, allergic reactions to dose administration are possible. Therefore, 
appropriate drugs and medical equipment to treat acute anaphylactic reactions must be immediately available, and study personnel must be trained to recognize and treat anaphylaxis.  
 
Recording of Daily Dosing and Missed Do ses During At-home Dose Administration  
Subjects will be instructed to record the date and approximate time of each dose administered 
at home. If a dose of investigational product is missed, subjects should contact [CONTACT_779], who will contact [CONTACT_7195], for further instructions.  
 
[IP_ADDRESS]  Reporting Product Complaints  
Any defects with the investigational product must be reported immediately to the MedImmune 
Product Complaint Department by [CONTACT_362153]. All defects will be communicated to MedImmune and investigated further with the Product 
Complaint Department. During the investigation of the product complaint, all investigational 
product must be stored at labeled conditions unless otherwise instructed.  
 
MedImmune contact [CONTACT_73302]: 
Email: [EMAIL_2361]  
Phone: +[PHONE_2692]  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  68 of 117  Template  18.0   
  
Mail: MedImmune  
Attn: Product Complaint Department 
One MedImmune Way, Gaithersburg, MD [LOCATION_003] [ADDRESS_824491] will be prepared in accordance with Good 
Manufacturing Practice (GMP) and local regulatory guidelines. Label text will be translated 
into local languages, as required.  
 
4.5.[ADDRESS_824492] be stored at 2; to 8; in their original container, including 
during transit to, and storage at, the subject’s  home. Investigational products do not contain 
preservatives and are supplied for single-dose use only. Investigational product should be protected from heat and light. The investigator or designee must confirm appropriate temperature conditions have been maintained during transit for all study treatment received and any discrepancies are reported and resolved before use of the study treatment.  
Only subjects enrolled in the study may receive st udy treatment and only authorized site staff 
may supply or administer study treatment. All study treatments must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff. The label on the investigational product kit specifies the appropriate storage.  
 
4.5.[ADDRESS_824493] will be administered at the study site by [CONTACT_619964] 
50 μg dose. Subjects are also required to dose at the study site on study day visits when 
predose assessments are required. Study site personnel will monitor compliance during these 
visits.  
 
Compliance during the at-home dosing period will be monitored by [CONTACT_619965]-diary review and drug accountability (returned unused vials) at each study visit.  
 
4.5.6 Accountability  
The investigator’s or site’s designated investig ational product manager is required to maintain 
accurate investigational product accountability reco rds. Upon completion of the study, copi[INVESTIGATOR_619942] s will be returned to MedImmune. All unused  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824494].  
Subjects will be randomized using a 2:1:2:[ADDRESS_824495] (MEDI0382 or placebo) must be administered within [ADDRESS_824496] nor any of the investigator or sponsor staff who are involved in the treatment or clinical evaluation of the subjects will be 
aware of the treatment received (ICH E9).  
 
In the event that treatment allocation for a subject becomes known to the investigator or other 
study staff involved in the management of study subjects, MedImmune must be notified 
immediately . 
 
4.6.3 Methods for Unblinding  
[IP_ADDRESS]  Unblinding in the Event of a Medical Emergency  
In the event of a medical emergency, the investigator may unblind an individual subject’s 
investigational product allocation. Instructions for unblinding an individual subject’s 
investigational product allocation are contained in the IWRS manual. In general, unblinding 
should only occur if management of the medical  emergency would be different based on the 
subject having received investigational product. In the majority of cases, the management of a medical emergency would be the same whether or not investigational product was received by 
[CONTACT_423]. If this was the case, the investigational product allocation should not be unblinded.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  70 of 117  Template  18.0   
  
In the event there is unblinding, the investigator should promptly document and explain to 
MedImmune the reason for any premature unblinding.  
 
MedImmune retains the right to unblind the treatment allocation for serious adverse events 
(SAEs) that are unexpected and are suspected to be causally related to an investigational product and that potentially require expedited reporting to regulatory authorities.  
 
If a subject’s investigational product allocation is unblinded to the blinded staff or blinded 
MedImmune study team, the subject should be discontinued from investigational product.  
 
[IP_ADDRESS]  Unblinding for Interim Analysis Purposes  
All personnel involved with the conduct of the study will remain blinded until database lock. 
The interim analysis will be conducted by [CONTACT_619966], SAS programmers, and a physic ian. The results will be reviewed by [CONTACT_619967] (URC). A limited number of sponsor personnel who are not involved in the conduct of the study will form the URC. Any study team members who have access to the unblinded analyses will not be involved in further conduct of the study.  
Additional details about the interim analysis and the URC will be provided in the interim 
analysis charter.  
In the event that emergent safety data require it, the sponsor’s core cross-functional safety 
team will have the capacity to introduce an ad-hoc review of unblinded safety data by [CONTACT_619968]. The conduct and composition of the URC w ill be the same as those for the interim 
analysis. The sponsor’s core cross-functional safety team in collaboration with the study statistician and the study physician will decide about the timing and the scope of the ad-hoc review. Analyses will be performed by [CONTACT_619969]. More details will 
be provided in the statistical analysis plan.  
4.7 Restrictions During the Study and Concomitant Treatment(s)  
The investigator must be informed as soon as possible about any medication taken from the 
time of screening until the final study visit. Any concomitant medication(s), including herbal preparations, taken during the study will be recorded in the eCRF.  
 
4.7.1 Permitted Concomitant Medications  
Investigators may prescribe concomitant medications or treatments deemed necessary to 
provide adequate supportive care except for those medications identified as “excluded” as 
listed in Section 4.7.2 . Specifically, subjects with T2DM should continue to take their 
antidiabetic medication (see inclusion criterion 4) at the regular dose prescribed and any other 
medication prescribed for the treatment of co-morbidities associated with T2DM.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824497] instance, 
rather than a prokinetic agent such as domperidone or metoclopramide (Section [IP_ADDRESS] ). 
Subjects on a stable dose (for at least 1 year) of high dose of vitamin E (> 400 IU) at the time 
of the baseline biopsy will be permitted to remain on this medication during the course of the study providing no changes are made to the dose ( Table 11 ). 
 
4.7.[ADDRESS_824498] consulting with the investigator.  
 
Use of the following medications will be restricted ( Table 11 ) or prohibited ( Table 12 ) as 
specified:  
 
Table 11 Restricted medications  
 
Medication/class of drug:  Usage (including limits for duration permitted and 
special situations in which it’s allowed ):  
Herbal preparations or  dietary supplements 
marketed for control of body weight or appetite  Concurrent or prior use within 1 week prior to the start of 
screening and during the study  
Systemic corticosteroids by [CONTACT_68058], intravenous, intra- articular, or intr amuscular route
 Within 3 months prior to star t of screening and during the 
study unless prescribed for a ve ry brief period of less than 
7 days  
Vitamin E (high doses > 400 IU)  Concurrent use, unless on a stable dose for at least [ADDRESS_824499] 1 year 
prior to baseline biopsy, and no changes made during study  
Domperidone and metoclopramide  Only to be used during th e study for the treatment of 
nausea and vomiting in the instance of intolerance to a centrally-acting anti-emetic
 
Insulin  Only to be used for treatment of severe hyperglycemia as 
rescue medicati on and according to local guidelines  
IU = International units, PPAR- γ = Peroxisome proliferator-activated receptor gamma  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  72 of 117  Template  18.0   
  
 
 
Table 12 Prohibited medications  
 
Prohibited medication/class of drug:  Usage  
Therapi[INVESTIGATOR_619943], ta moxifen, amiodarone, or 
long-term use of tetracyclines  Within 3 months of baseline biopsy until the end of the 
study. In the case of tetracycli nes, these drugs are restricted 
during the study unless prescribed for a very brief period of 
less than 7 days  
Therapi[INVESTIGATOR_619944] r investigation for the 
treatment of NASH (except for SGLT-2 inhibitors and PPAR- γ agonists), such as obeticholic acid
 Within [ADDRESS_824500] containing therapi[INVESTIGATOR_619945] 3 months of baseline biopsy until the end of the study
 
Drugs approved for weight loss (eg, orlistat, 
bupropi[INVESTIGATOR_2394]/naltrexone, phentermine-topi[INVESTIGATOR_052], 
phentermine, lorcaserin), as well as those drugs 
used off-label  Concurrent or previous use within the last 3 months prior 
to the start of screening and during the study  
GLP-1 = glucagon-like peptide-1; NAFLD = Non-alcoholic fatty liver  disease; NASH = Non-alcoholic 
steatohepatitis; PPAR- γ = Peroxisome proliferator-activated receptor gamma; SGLT-2 = Sodium-glucose 
co-transporter [ADDRESS_824501] deviation (SD), median, 
minimum, and maximum. Baseline values will be defined as the last assessment prior to the 
first administration of investigational product.  Additional details will be described in the 
statistical analysis plan.  
 
4.8.2 Sample Size  
The primary objective of the study is safety, but sample size and power are calculated on 
pharmacodynamic endpoint HFF. Assuming 20% treatment difference on percent change in HFF with SD = 20%, and assuming a 25% dro pout rate, 24 subjects per group will provide 
about 83% power to detect a treatment difference between a MEDI0382 group and the 
placebo (alpha = 0.05, 2-sided). No multiplicity adjustment for alpha is planned.  
 
4.8.3 Efficacy  
[IP_ADDRESS]  Efficacy Analysis  
The efficacy analyses will be base d on the Intent-t o-treat population.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  73 of 117  Template  18.0   
  
The pharmacodynamic endpoint, percent change from baseline in HFF at Week 19, is an 
efficacy endpoint for the study. The percent change from baseline to Week 19 in HFF will be analyzed using analysis of covariance (ANCOVA) adjusting for treatment and baseline value. For the other pharmacodynamic and biomarker endpoints that are continuous variables, 
similar ANCOVA analyses as the above analysis  will be carried out. For ANCOVA analyses, 
last observation carried forward (LOCF) met hod will be applied for efficacy endpoints to 
handle missing data, that is, a missing endpoint will be replaced with the last available  
post-baseline measurement prior to the missing endpoint.  
 
[IP_ADDRESS]  Additional Analyses of the Efficacy Endpoint  
The sensitivity analysis [ADDRESS_824502] of rep eating the descriptive analysis and the ANCOVA 
model on the same population used for the main analysis but including only data in the on- 
treatment phase. It is performed at interim analysis and at final analysis.  
 
The sensitivity analysis 4 consists on repea ting the descriptive analysis and the ANCOVA 
model on the Per-protocol population. It is performed at interim analysis and at final analysis.  
 
4.8.4 Safety  
[IP_ADDRESS]  Analysis of Adverse Events  
Safety analyses will be based on As-treated  population. Treatment-emergent AEs and SAEs 
will be coded by [CONTACT_619970] 
(MedDRA), and the type, incidence, severity and relationship to study investigational product will be summarized by [CONTACT_619971]. 
Specific AEs will be counted once for each subject for calculating percentages. In addition, if 
the same AE occurs multiple times within a subject, the highest severity and level of relationship observed will be reported.  
Other safety data, such as vital signs, clinical laboratory data, and dECG will be descriptively 
summarized at each time point by [CONTACT_3148].  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  74 of 117  Template  18.0   
  
[IP_ADDRESS]  Analysis of Clinical Laboratory Parameters  
Laboratory parameters will be assessed at ba seline as well as throughout the study. Laboratory 
parameters will be assessed by [CONTACT_619972], as well as descriptively over time.  
 
Hepatic safety analyses:  
 
 Proportion of subjects with marked changes (5 × ULN, 8 × ULN) from baseline in ALT 
and AST  
 Mean changes from baseline to end of treatment in ALT and AST levels  
 
4.8.5 Analysis of Immunogenicity/Pharmacokinetics  
Subjects who have at least one measurable concentration time point of investigational product 
will be used for this analysis.  
 
Pharmacokinetic parameters such as, but not limited to, C max, time to maximum observed 
plasma drug concentration (t max), and AUC, per group on the last day of dosing, may be 
estimated from plasma concentration-time data for MEDI0382 if data permit. Descriptive 
statistics will be generated for pharmacokinetic parameters for MEDI0382 in group.  
Additional summary statistics on predose concentr ations and specific postdose concentrations 
may be listed, if data permits, by [CONTACT_19313], treatment and day and will be summarized as maximum, minimum, arithmetic mean, and geometric mean.  
The number and percentage of subjects with confirmed positive serum antibodies to 
MEDI0382 will be reported by [CONTACT_619973]. The potential impact of ADA on MEDI0382 pharmacokinetics, efficacy and safety will be evaluated.  
ADA incidence rate and titer will be tabulated  by [CONTACT_3148]. Samples confirmed positive for 
ADA will be analyzed for titer and reported.  
 
4.8.[ADDRESS_824503] completed approximately 
19 weeks of treatment.  
 
The purpose of this interim analysis is to help inform further clinical development; no changes 
will be made to this study unless a safety si gnal is observed. The interim analysis will be 
described in the interim analysis charter. The interim analysis results will not be provided to 
the investigator.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824504] a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, an abnormal laboratory finding), symptom (eg, nausea, chest pain), or 
disease temporally associated with the use of a medicinal product, whether or not considered 
related to the medicinal product.  
 
The term AE is used to include both serious and non-serious AEs and can include a 
deterioration of a pre-existing medical occurrence. An AE may occur at any time, including run-in or washout periods, even if no study treatment has been administered.  
 
Elective treatment or surgery or preplanned treatment or surgery (that was scheduled prior to 
the subject being enrolled into the study) for a documented pre-existing condition that did not 
worsen from baseline is not considered an AE (serious or non-serious). An untoward medical event occurring during the prescheduled elective procedure or routinely scheduled treatment should be recorded as an AE or SAE.  
 
5.2 Definition of Serious Adverse Events  
An SAE is any AE that:  
 
 Results in death  
 Is immediately life-threatening  
 Requires inpatient hospi[INVESTIGATOR_1081]  
 Results in persistent or significant disability/incapacity  
 Is a congenital anomaly/birth defect in offspring of the subject  
 Is an important medical event that may jeopardize the subject or may require medical 
intervention to prevent one of the outcomes listed above  
 
Medical or scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in this situation. Examples of medi cally important events are intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions 
that do not result in hospi[INVESTIGATOR_602]; or development of drug dependency or drug abuse.  
 
5.[ADDRESS_824505], possible etiologies, and whether the event meets criteria of an  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  76 of 117  Template  18.0   
  
SAE and therefore requires immediate notification to MedImmune (see Section 5.4). See 
Section 5.2 for the definition of SAEs and Appendix B for guidelines for assessment of 
severity and relationship.  
 
If an AE evolves into a condition that meets the regulatory definition of “serious,” it will be 
reported on the SAE Report Form.  
 
5.3.[ADDRESS_824506]’s la st AE assessment or other assessment/visit as 
appropriate in the study are followed up by [CONTACT_24549], but without further recording in the eCRF. MedI mmune retains the right to request additional 
information for any subject with ongoing AE(s)/SAE(s) at the end of the study, if judged necessary.  
 
5.3.[ADDRESS_824507] or reported in response to the open question 
from the study site staff: ‘Have you had any health problems since the previous visit/you were 
last asked?’ or revealed by [CONTACT_178557]. When 
collecting AEs, the recording of diagnoses is preferred (when possible) to recording a list of signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms that are not generally part of the diagnosis,  the diagnosis and each sign or symptom will be 
recorded separately.  
 
5.3.5 Adverse Events Based on Examination and Tests  
The results from the protocol-mandated laboratory tests and vital signs will be summarized in 
the CSR. An abnormal laboratory finding (including dECG finding) that requires medical 
intervention by [CONTACT_093], or a finding judged by [CONTACT_169974]. If clin ical sequelae are associated with a laboratory 
abnormality, the diagnosis or medical condition should be reported (eg, renal failure,  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  77 of 117  Template  18.0   
  
hematuria) not the laboratory abnormality (eg, elevated creatinine, urine red blood cell 
increased)  
 
If deterioration in a laboratory value/vital sign is  associated with clinical signs and symptoms, 
the sign or symptom will be reported as an AE and the associated laboratory result/vital sign will be considered as additional information. Wherever possible the reporting investigator 
uses the clinical, rather than the laboratory term (eg, anemia versus low hemoglobin value). In 
the absence of clinical signs or symptoms, clinically relevant deteriorations in non-mandated parameters should be reported as AE(s).  
 
Any new or aggravated clinically relevant abnormal medical finding at a physical examination 
as compared with the baseline assessment will be reported as an AE.  
 
5.3.6 Potential Hy’s Law and Hy’s Law  
Cases where a subject shows elevations in liver biochemistry may require further evaluation 
and occurrences of AST or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN will need to be 
reported as SAEs. Please refer to Appendix D for further instruction on cases of increases in 
liver biochemistry and evaluation of Hy’s Law.  
 
5.[ADDRESS_824508], or to the study procedure(s). All SAEs will be recorded in the eCRF.  
 
If any SAE occurs in the course of the study, then investigators or other site personnel must 
inform the appropriate sponsor representative(s) within 1 day, ie, immediately but no later than 24 hours after becoming aware of the event.  
 
The designated study representative works with the investigator to ensure that all the 
necessary information is provided to the sponsor’s Patient Safety data entry site within  
1 calendar day of initial receipt for fatal and life-threatening events and within 5 calendar days 
of initial receipt for all other SAEs.  
 
For fatal or life-threatening AEs where important or relevant information is missing, active 
follow-up is undertaken immediately. Investigator s or other site personnel inform sponsor 
representatives of any follow-up information on a previously reported SAE within 1 calendar 
day, ie, immediately but no later than 24 hours after becoming aware of the event.  
 
Once the investigators or other site personnel indicate an AE is serious in the eCRF, an 
automated email alert is sent to inform the designated sponsor representative(s).  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  78 of 117  Template  18.0   
  
If the eCRF is not available, then the investigator or other study site personnel reports an SAE 
to the appropriate sponsor representative by [CONTACT_756]. The sponsor representative will advise the investigator/study site personnel how to proceed.  
 
The reference document for definition of expectedness/listedness is the IB for the 
MedImmune drug.  
 
5.[ADDRESS_824509] in excess of 
that specified in the IB, unless otherwise specified in this protocol.  
 
 An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE modules in the eCRF and on the Overdose eCRF module.  
 An overdose without associated symptoms is only reported on the Overdose eCRF 
module.  
 
If an overdose on a MedImmune investigational product occurs during the course of the study, 
then the investigator or other site personnel should inform appropriate sponsor representatives immediately, but no later than 24 hours after becoming aware of the event.  
 
The designated sponsor representative works with the investigator to ensure that all relevant 
information is provided to the sponsor’s Patient Safety data entry site.  
 
For overdoses associated with an SAE, the st andard reporting timelines apply; see Section 5.4. 
For other overdoses (ie, those not associated w ith an AE or SAE), reporting must occur within 
30 days.  
 
5.5.2 Pregnancy  
All pregnancies and outcomes of pregnancy should be reported to the sponsor except for:  
 
 If the pregnancy is discovered before the study subject has received any investigational 
product.  
 Pregnancies in the partner of male subjects.  
 
[IP_ADDRESS]  Maternal Exposure  
If a subject becomes pregnant during the course of the study investigational product should be 
discontinued immediately.  
 
Pregnancy itself is not regarded as an AE unless there is a suspi[INVESTIGATOR_429001] a contraceptive medication.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  79 of 117  Template  18.0   
  
Congenital abnormalities/birth defects and spontaneous miscarriages should be reported and 
handled as SAEs. Elective abortions without complications should not be handled as AEs. The outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth or congenital abnormality) should be followed up and documented even if the 
subject was discontinued from the study.  
 
If any pregnancy occurs during the course of the study, then the investigator or other site 
personnel will inform the appropriate sponsor representatives within 1 day, ie, immediately 
but no later than 24 hours after becoming aware of the event.  
 
The designated study representative works with the investigator to ensure that all relevant 
information is provided to the sponsor’s Patient Safety data entry site within 1 or 5 calendar 
days for SAEs (see Section 5.4) and within [ADDRESS_824510].  
 
Medication error includes situations where an error:  
 
 Occurred  
 Was identified and intercepted before the subject received the drug  
 Did not occur, but circumstances were recognized that could have led to an error 
Examples of events to be reported in clinical studies as medication errors:  
 Drug name [CONTACT_2976] (ie, instead of receiving the investigational product, the subject  
received a drug that has a similar-sounding name)  
 Dispensing error, eg, medication prepared incorrectly, even if it was not actually given to 
the subject  
 Drug not administered as indicated, for example, wrong route or wrong site of 
administration  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  80 of 117  Template  18.0   
  
 Drug not taken as indicated, eg, tablet dissolved in water when it should be taken as a 
solid tablet  
 Drug not stored as instructed, eg, kept in the refrigerator when it should be at room 
temperature  
 Wrong subject received the medication (excluding IWRS errors)  
 Wrong drug administered to subject (excluding IWRS errors)  
 
Examples of events that do not require reporting as medication errors in clinical studies:  
 
 Errors related to or resulting from IWRS - including those which lead to one of the above 
listed events that would otherwise have been a medication error  
 Subject accidentally missed drug dose(s), eg, forgot to take medication  
 Accidental overdose (will be captured as an overdose)  
 Subject failed to return unused medication or empty packaging  
 Errors related to background and rescue medication, or standard of care medication in 
open label studies, even if an AZ or MedImmune product  
 
Medication errors are not regarded as AEs, but AEs may occur as a consequence of the 
medication error.  
 
If a medication error occurs in the course of the study, then the investigator or other site 
personnel informs the appropriate MedImmune re presentatives within 1 day, ie, immediately 
but no later than 24 hours of when he or she becomes aware of it.  
 
The designated MedImmune representative works with the investigator to ensure that all 
relevant information is completed within 1 or 5 calendar days if there is an SAE associated 
with the medication error (see Section 5.4) and within [ADDRESS_824511] is entered into the study, a MedImmune representative will review and 
discuss the requirements of the protocol and related documents with the investigational staff 
and also train them in any study-speci fic procedures and system(s) utilized.  
 
The Principal Investigator [INVESTIGATOR_406787], and that any new information relevant to the performance of this study is 
forwarded to the staff involved.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824512] of all individuals involved in the study 
(medical, nursing, and other staff).  
 
6.[ADDRESS_824513] regular contacts with the study site, 
including visits to:  
 
 Provide information and support to the investigator(s).  
 Confirm that fac ilities remain  acceptable.  
 Confirm that the investigational team is adhering to the protocol, that data are being 
accurately and timely recorded in the eCRFs, that biological samples are handled in 
accordance with the Laboratory Manual and that investigational product accountability checks are being performed.  
 Perform source data verification (a comparison of the data in the eCRFs with the subject’s 
medical records at the hospi[INVESTIGATOR_7117], and other records relevant to the study) 
including verification of informed consent of participating subjects. This will require direct access to all original records for each subject (eg, clinic charts).  
 Ensure withdrawal of informed consent to the use of the subject’s biological samples is 
reported and biological samples are identified and disposed of/destroyed accordingly, and the action is documented, and reported to the subject.  
 
The MedImmune representative will be available be tween visits if the investigator(s) or other 
staff at the site needs information and advice about the study conduct.  
 
6.2.1 Source Data 
Refer to the Clinical Study Agreement (CSA) for location of source data.  
 
6.2.2 Study Agreements 
The Principal Investigator [INVESTIGATOR_144109]/the site shoul d comply with all the terms, conditions, and 
obligations of the CSA, or equivalent, for this study. In the event of any inconsistency between this protocol and the CSA, the terms of protocol shall prevail with respect to the conduct of the study and the treatment of subjects and in all other respects, not relating to study conduct or treatment of subjects, the terms of the CSA shall prevail.  
 
Agreements between MedImmune and the Principal Investigator [INVESTIGATOR_169937]-related procedures can take place, or subjects are enrolled.  
 
6.2.3 Archiving of Study Documents 
The investigator follows the principles outlined in the CSA.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824514] protocol-specified visit/assessment or assessed for the primary end 
point of the study, regardless of the number of doses of investigational product that was 
received.  
 
Subjects will be considered not to have completed the study if consent was withdrawn or the 
subject was lost to follow-up (see Section 4.1.6 and Section 4.1.7 ). 
 
The end of the study (“study completion”) is defined as the date of the last protocol-specified 
visit/assessment (including telephone contact) for the last subject in the study.  
 
6.[ADDRESS_824515]’s physician access to a medical monitor [ADDRESS_824516]’s health is d eemed to be at risk. In this situation, when a 
subject presents to a medical facility where the treating physician or health care provider requires access to a physician who has knowledge of the investigational product and the clinical study protocol and the Principal Investigator [INVESTIGATOR_125234], the treating physician or health care provider can contact a medical monitor through this system, which is managed by a third party vendor.  
[ADDRESS_824517] data that are relevant to the study, eg, demographic  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824518]’s informed consent. The ICF will 
incorporate (or, in some cases, be accompanied by a separate document incorporating) wording that describes how subject data will be  collected, used, and distributed in compliance 
with relevant data protection and privacy legi slation. Data (clinical and biological sample) 
from this study may be used and may be combined with results from other studies for additional scientific-related research, based on agreement from the subject as defined in the 
informed consent.  
 
Extra precautions will be taken to preserve confidentiality and prevent genetic data being 
linked to the identity of the subject. MedImmune will not provide individual genotype results 
to subjects, any insurance company, any employer, their family members, general physician or 
any other third party, unless required to do so by [CONTACT_2371] . 
 
7.2 Ethics and Regulatory Review  
The IRB/IEC responsible for each site must review and approve the final study protocol, 
including the final version of the ICF and any other written information and/or materials to be provided to the subjects. The IRB/IEC must also approve all advertising used to recruit subjects for the study. The investigator is responsible for submitting these documents to the applicable IRB/IEC and distributing them to the study site staff.  
The opi[INVESTIGATOR_1100]/IEC must be given in writing. The investigator must provide a copy of 
the written approval to MedImmune before enrolment of any subject into the study.  
 
MedImmune should approve any substantive modifications to the ICF that are needed to meet 
local requirements.  
 
If required by [CONTACT_427], the protocol must be re-approved by [CONTACT_1201]/IEC annually.  
 
Before the study is initiated, MedImmune will ensure that the national regulatory authority in 
each country has been notified and their approval has been obtained, as required. MedImmune will provide safety updates/reports according to local requirements, including suspected unexpected serious adverse reactions where rele vant, to regulatory authorities, IRB/IEC, and 
principal investigators.  
Each Principal Investigator [INVESTIGATOR_619946]/IEC. MedImmune will provide this information to the Principal Investigator [INVESTIGATOR_33090]/she can meet these reporting requirements.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824519] will be obtai ned through a written and verbal explanation 
process that addresses all elements require d by [CONTACT_12212]/GCP. MedImmune will develop a core 
ICF for use by [CONTACT_169976]. MedImmune must approve any 
modifications to the ICF that are needed to meet local requirements.  
 
The Principal Investigator(s) at each site will:  
 
 Ensure each subject is given full and adequate oral and written information about the 
nature, purpose, possible risk and benefit of the study  
 Ensure each subject is notified that they are free to discontinue from the study at any time  
 Ensure that each subject is given the opportunity to ask questions and allowed time to 
consider the information provided  
 Ensure each subject provides signed and date d informed consent before conducting any 
procedure specifically for the study  
 Ensure the original, signed ICF is stored in the Investigator’s Study File  
 Ensure a copy of the signed ICF is given to the subject  
 Ensure that any incentives for subjects who participate in the study as well as any 
provisions for subjects harmed as a consequence of study participation are described in 
the ICF that is approved by [CONTACT_2717]/IEC  
 
7.[ADDRESS_824520] be documented in a study protocol 
amendment.  
 
For a substantial change to the protocol, MedI mmune will distribute amended versions of the 
protocol to the Principal Investigator(s). Before implementation, amended protocols must be approved by [CONTACT_33149]/IEC (see Section 7.2) and reviewed as per local regulatory authority 
requirements. The IRB/IEC must also approve revisions to the ICF, advertising, and any other written information and/or materials resulting from the change to the protocol.  
Any non-substantial changes will be communicated to or approved by [CONTACT_9906]/IEC.  
 
7.5 Audits and Inspections  
Authorized representatives of MedImmune, a regulatory authority, or an IRB/IEC may 
perform audits or inspections at the site, including source data verification. The purpose of an audit or inspection is to systematically and independently examine all study-related activities and documents, to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported according to the protocol, GCP, guidelines of the  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  85 of 117  Template  18.0   
  
International Conference on Harmonisation (ICH), and any applicable regulatory 
requirements. The investigator will contact [CONTACT_24553] a regulatory agency about an inspection at the site.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824521], in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet (London, England). 2018;391([ZIP_CODE]):2607-18.  
 
Angulo P. GI epi[INVESTIGATOR_623]: nonalcoholic fatty liver disease. Alimentary pharmacology & 
therapeutics. 2007;25(8):883-9.  
 
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P et 
al. Liver Fibrosis, but No Other Histologic Feat ures, Is Associated With Long-term Outcomes 
of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389- 
97.e10.  
 
Armstrong MJ, Hull D, Guo K, Barton D, Yu J, Tomlinson J et al. Effect of liraglutide on 
adipose insulin resistance and hepatic de- novo lipogenesis in non-alcoholic steatohepatitis: 
substudy of a phase 2, randomised placebo-controlled trial. The Lancet. 2014;383S21.  
 
Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R et al. Liraglutide safety and 
efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet (London, England).  
2016;387([ZIP_CODE]):679-90.  
 
Astrup A, Carraro R, Finer N, Harper A, Kunes ova M, Lean ME et al. Safety, tolerability and 
sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.  
International journal of obesity (2005). 2012;36(6):843-54.  
 
Bellentani S, Scaglioni F, Marino M, Bedogni G. Epi[INVESTIGATOR_228746]-alcoholic fatty liver 
disease. Digestive diseases (Basel, Switzerland). 2010;28(1):155-61.  
 
Bellentani S. The epi[INVESTIGATOR_228746]-alcoholic fatty liver disease. Liver international : 
official journal of the International Association for the Study of the Liver. 2017;[ADDRESS_824522] 181- 4. 
 
Cegla J, Troke RC, Jones B, Tharakan G, Kenkre J, McCullough KA et al. Coinfusion of low- 
dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes.  
2014;63(11):3711-20.  
 
Center for Drug Evaluation and Research. By[CONTACT_619974]. 2005.  
Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic 
steatohepatitis: Current knowledge and implica tions for management. World journal of 
hepatology. 2017;9(11):533-43.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  87 of 117  Template  18.0   
  
Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z et al. Increased risk of mortality by 
[CONTACT_619975]: Systematic review and meta-analysis.  
Hepatology (Baltimore, Md). 2017;65(5):1557-65.  
 
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epi[INVESTIGATOR_619947]. 
Hepatology (Baltimore, Md). 2018;67(1):123-33.  
 
Habegger KM, Stemmer K, Cheng C, Muller TD, Heppner KM, Ottaway N et al. Fibroblast 
growth factor 21 mediates specific glucagon actions. Diabetes. 2013;62(5):1453-63.  
 
Lynch AM, Pathak N, Pathak V, O'Harte FP,  Flatt PR, Irwin N et al. A novel DPP IV- 
resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes- protective effects in high-fat-fed mice me diated through glucagon and GLP-1 receptor 
activation. Diabetologia. 2014;57(9):1927-36.  
 
Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. 
Current pharmaceutical design. 2013;19(29):5250-69.  
 
Meisamy S, Hines CD, Hamilton G, Sirlin CB, Mc Kenzie CA, Yu H et al. Quantification of 
hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of 
fat: blinded comparison with MR spectroscopy. Radiology. 2011;258(3):767-75.  
 
Mishra A, Younossi ZM. Epi[INVESTIGATOR_619948]-alcoholic Fatty Liver 
Disease. Journal of clinical and experimental hepatology. 2012;2(2):135-44.  
 
Neuschwander-Tetri BA. Non-alcoholic fatty  liver disease. BMC medicine. 2017;15(1):45. 
Pais R, Barritt ASt, Calmus Y, Scatton O, Runge T, Lebray P et al. NAFLD and liver 
transplantation: Current burden and expected challenges. Journal of hepatology.  
2016;65(6):1245-57.  
 
Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A et al. Association of noninvasive 
quantitative decline in liver fat content on MRI with histologic response in nonalcoholic 
steatohepatitis. Therapeutic advances in gastroenterology. 2016;9(5):692-701.  
 
Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C et al. Effect of 
Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 
Diabetes: The Lira-NAFLD Study. The Journal of clinical endocrinology and metabolism. 
2017;102(2):407-15.  
 
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L et al. Hypoglycemia and 
diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine 
Society. The Journal of clinical endocrinology and metabolism. 2013;98(5):1845-59.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  88 of 117  Template  18.0   
  
Valdecantos MP, Pardo V, Ruiz L, Castro-Sanchez L, Lanzon B, Fernandez-Millan E et al. A 
novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice. Hepatol ogy (Baltimore, Md). 2017;65(3):950-68.  
 
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-B ertot L, Torres-Gonzalez A, Gra-Oramas B, 
Gonzalez-Fabian L et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gast roenterology. 2015;149(2):367-78.e5; quiz e14- 
5. 
 
Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapi[INVESTIGATOR_619949] U.S. Hepatology (Baltimore, Md). 2014;59(6):2188-95.  
 
Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS et al. Oxyntomodulin 
increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. International Journal Of Obesity. 2006;301729.  
 
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epi[INVESTIGATOR_619950]-Meta-analytic assessment of prevalence, incidence, and 
outcomes. Hepatology (Baltimore, Md). 2016;64(1):73-84.  
 
 
9 CHANGES TO THE PROTOCOL  
9.1 Protocol Amendment 6  
The following change has been incorporated into the current version, considered Protocol 
Amendment 6, of the protocol.  
 
The change is considered non-substantial.  
Title page: The medical monitor was changed from [COMPANY_003]  to [COMPANY_003] . 
9.[ADDRESS_824523] been corrected and are not noted below.  
 
The following change is considered substantial:  
 
1. Section 3.1.1 (Overview) and Section 4.8.6 (Interim Analysis): to improve the 
distribution of subjects with a sufficient range of disease to be included in the interim  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  89 of 117  Template  18.0   
  
analysis, the timeframe was changed from 13 weeks to 19 weeks of completed 
treatment for approximately 39 subjects (a change from 30 subjects).  
 
The following changes are considered non substantial:  
 
2. Table 5 (Screening Schedule of Procedures) Footnote ‘f’ and Section [IP_ADDRESS] 
(Magnetic Resonance Imaging [Including MRI- PDFF]): to allow for repeat screening 
MRI the following text was added ‘ If the screening MRI is determined to be of 
inadequate image quality by [CONTACT_619976] ’. 
 
3. Section 4.2.2 (Randomized Treatment Period): to maintain subject safety, and to allow 
for continued data collection during the COVID-[ADDRESS_824524] opportunity and within 7 days of the original D78 scheduled date, and to allow D133 assessments to be collected within a 2 days window (7 days 
for MRI), and if [ADDRESS_824525] been corrected and are not noted below.  
The following changes are considered substantial:  
 
Body weight, although collected, was not described as a specific objective in the original 
protocol. Body weight changes are an important parameter for the assessment of MEDI0382 
in NASH and therefore body weight and BMI have been called out as a distinct objective and included as a dose response endpoint.  
 
1 Table 2 (Secondary Objectives and Associated Endpoints): change in body weight and 
BMI added as a new secondary objective.  
2 Table 2 (Secondary Objectives and Associated Endpoints): body weight added to the dose 
response endpoints.  
 
Due to the nature of the study population, some subjects will be receiving prescribed 
medication which could result in a positive sc reen for drugs of abuse. However, where 
medication is prescribed and does not indicate an addiction or safety concern the Investigator  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824526] at their discretion. Exclusion Criterion 14 was amended as 
follows:  
 
3 Section 4.1.3 (Exclusion Criteria): reworded from History of substance dependence likely 
to impact subject safety or compliance with study procedures, or positive screen for drugs of abuse at screening to History of substance dependence or a positive screen for drugs of 
abuse, likely to impact subject safety or compliance with study procedures, at the 
discretion of the Investigator.  
 
The following changes are considered non-substantial:  
 
4 Table 2 (Secondary Objectives and Associated Endpoints): liver sagittal diameter and 
liver transversal diameter changed to abdominal sagittal diameter and abdominal 
transversal diameter . 
CCI 
 
 
 
 
 
 
  
 
  
 
analysis plan changed to interim analysis charter.  
9 Section [IP_ADDRESS] (Persistent Hyperglycemia): DPP-4i should be avoided and alternative 
options considered.  
10 Section 3.2.3 (Rationale for Endpoints): rati onale for the addition of body weight and 
BMI to secondary endpoints.  
11 Section 4.1.5 (Screen Failures): text added to cl arify that the same E-code will be used for 
subjects who are rescreened.  
12 Section 4.1.8 (Study Stoppi[INVESTIGATOR_2121]): clarification to text due to site feedback.  
13 Table 5 (Screening Schedule of Procedures):  
 Clarification that virology at a minimum includes hepatitis B surface antigen, 
hepatitis C virus antibody; HIV-1 and HIV-2  
 Footnote ‘c’: clarification that screening dECG measurements should be performed 
after the subject has rested in the supi[INVESTIGATOR_21683] 10 minutes.   
    
 
    
 
Section 4.8.6 (Interim Analysis): interim unblinding  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  91 of 117  Template  18.0   
  
 Footnote ‘f’: MRI (including MRI-PDFF) changed to MRI-PDFF . Change 
implemented to avoid confusion regarding which screening MRI protocol should be 
used.  
 Footnote ‘i’: text added to confirm that if multiple alcohol screening tests are 
performed and conflicting results occur any positive result should be documented.  
14 Table 6 (MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of Procedures) 
and Table 7 (MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of 
Procedures) footnotes ‘f’ and ‘g’: to allow for flexibility, dECG and vital sign predose collection times changed to allow assessments within 20 minutes, respectively.  
15 Table 8 (Schedule of Follow-up Procedures) footnote ‘b’: the requirement for a HbA1c 
sample for subjects requiring an ADA follow-up sample was removed. This assessment is 
not required to interpret the immunogenicity profile during safety follow-up.  
16 Section [IP_ADDRESS] (Vital Signs): to allow flexibility, it was clarified that blood pressure 
should be performed after the subject has rested in the supi[INVESTIGATOR_21683] 10 
minutes.  
17 
 
 
18 Section [IP_ADDRESS] (Fibroscan): according to the Imaging Manual removed because this is 
inaccurate.  
19 Section 4.3.6 (Clinical Laboratory Tests): nitrites added, as they were previously omitted 
from the urinalysis tests . Low molecular weight adiponectin removed to reflect laboratory 
standard practice.  
20 
 
21 Section [IP_ADDRESS] (Reporting Product Complaints): telephone and fax numbers removed to 
reflect organisational changes.  
22 Section [IP_ADDRESS] (Unblinding for Interim Analysis Purposes): text updated to reflect the 
unblinding plans. Specifically, the following text was added: The conduct and 
composition of the URC will be the same as those for the interim analysis. The sponsor’s 
core cross-functional safety team in collaboration with the study statistician and the study 
physician will decide about the timing and the scope of the ad-hoc review.  
23 Section [IP_ADDRESS] (Additional Analyses of the Efficacy Endpoint): additional sensitivity 
analyses of the efficacy endpoint were added.  
24 Section 6.5 (Medical Monitor Coverage): clarification to the text that the telephone 
number will not be toll-free.  
25 Appendix E (Genetic Research): changes made to informed consent description to clarify 
that a single informed consent document will be used during the study. This single 
document enables a subject to decide whether to be included in the optional genetic and non-genetic samples.  
9.[ADDRESS_824527] been incorporated into the current version of the protocol.  CCI CCI 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  92 of 117  Template  18.0   
  
Text revisions resulting from this ame ndment are incorporated in the body of 
Protocol Amendment 3.  
 
All changes are considered non-substantial a nd that there are no substantial changes.  
 
1 Section 3.1.1 (Overview): the study flow diagram was corrected to accurately reflect the 
numbers of subjects per group.  
2 Section 4.1.3 (Exclusion Criteria): criterion 32 incorrectly included, text is for 
information only, criterion numbering has been removed.  
3 Section 4.1.6 (Withdrawal from the Study) and Section 4.1.7 (Discontinuation of 
Investigational Product): clarification to text to specify that subjects who discontinue early, but are not continuing with study assessments, should in addition to the Early 
Discontinuation Visit return for a follow-up visit. Text regarding 3 MRIs was also 
clarified.  
4 Section [IP_ADDRESS] (Magnetic Resonance Imaging [Including MRI-PDFF]) and Section  
[IP_ADDRESS] (Fibroscan): Table 8 added as a cross reference.  
5 Table 6 (MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of Procedures), 
Table 7 (MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures), 
Section [IP_ADDRESS] (Dose Preparation Steps), Table 10 (MEDI0382 and Placebo Dose Preparation) and Section 4.6.2 (Methods to Ensure Blinding): to mitigate the need for unblinded study personnel the 50 μg matched placebo dose will now require dilution. 
Text stating that placebo does not require dilution and text describing unblinded study 
personnel has been removed.  
6 Table 8 (Schedule of Follow-up Procedures):  
(a) Footnote ‘e’ updated to specify that subjects who discontinue early, but are not 
continuing with study assessments, should also return for a follow-up visit.  
(b) Clarification added to footnote ‘f’ to clarify that only [ADDRESS_824528].  
(c) Footnote ‘g’ added to clarify the timing of the pharmacokinetic sample.  
7 Appendix D (Actions Required in Cases of Increases in Liver Biochemistry and 
Evaluation of Hy’s Law): to the lab kit table the requirement for IgM anti-HCV testing was removed and a footnote added to confirm when HCV RNA testing is required.  
 
9.[ADDRESS_824529] been reflected in 
the protocol synopsis. For consistency EDC was changed to eCRF and SID to E-code 
throughout the protocol and any reference to a CRO was removed.  
 
Changes to the protocol considered substantial are:  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  93 of 117  Template  18.0   
  
1 Section 2.2 (Secondary Objective and Associated Endpoints): ‘percent change’ added to 
the pharmacodynamics endpoints for clarification.  
2 
 
3 Section 4.1.6 (Withdrawal from the Study) and 4.1.7 (Discontinuation of Investigational 
Product): text added to clarify the process in the event of a subject withdrawal. If only the 
investigational product is withdrawn but the subjects continues they should complete an 
Early Discontinuation visit and if possible all scheduled assessments, however, if the subject wishes to withdraw completely the investigator should ask them to return for an Early Discontinuation Visit. The number of MRI should not exceed [ADDRESS_824530] 
randomized into the study  
4 Table 6 (MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of Procedures):  
(a) HbA1c and fasting lipid profile assessments added to D78.  
(b) Adiponectin assessments added to D1, D78, and D133.  
5 Table 7 (MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures):  
(a) HbA1c and fasting lipid profile assessments added to D78.  
(b) Adiponectin assessments added to D1, D78, and D133.  
6 Table 8 (Schedule of Follow-up Procedures):  
(a) Calcitonin assessment added with corresponding footnote.  
(b) Assessments, and corresponding footnote, for IP accountability, fasting MRI-PDFF 
(including specification to not exceed 3 MRI following randomization), fibroscan, 
and pharmacokinetics added for those subjects completing the Early Discontinuation 
Visit.  
(c) Footnoted the requirement for HbA1c to be taken to evaluate the subjects glycemic 
control.  
7 
 
 
8 Section 4.3.12 (Estimate of Volume of Blood to be Collected): total blood volumes were 
updated to reflect additional sampling, approximately 461 mL, plus an optional 60 mL for the MEDI0382 300 μg/matched placebo group and 557 mL, plus an optional 60 mL for 
the MEDI0382 600 μg/matched placebo group.  
9 Section 5.3.1 (Time Period for Collection of Adverse Events) and Table 5: in the previous 
amendment AEs and SAEs were to be collected from signed informed consent and first dose of investigational product. This has been changed to only SAEs to be collected from signed informed consent and first dose of investigational product.  
 
 
Changes considered minor are provided below:  
 
10 Section 3.1.1 (Overview): the study flow diagram was updated to include the run-in 
period with accompanying footnote and total treatment duration.  CCI CCI 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  94 of 117  Template  18.0   
  
11 Section 3.1.1 (Overview) and (Interim Analysis): interim analysis text updated to say ’[ADDRESS_824531] completed approximately 13 weeks of treatment’  
12 Section 4.1.2 (Exclusion Criteria): exclusion criterion [ADDRESS_824532] research organization (C RO), or study site employee, or close 
relatives of any of the aforementioned employees to Any [COMPANY_008], MedImmune, or 
study site employee, or close relatives of any of the aforementioned employees. The 
update was made to reflect organizational changes.  
13 Section 4.1.4 (Subject Enrollment and Randomization), Table 5: SID number changed to 
E-code for consistency.  
14 New Section 4.1.5 (Screen Failures): section added to clarify how screening failures will 
be handled during the study.  
15 Section [IP_ADDRESS] (Physical Examination): text changed to clarify that clinically significant 
physical examination findings should be recorded as AEs.  
16 Section [IP_ADDRESS] (Digital Electrocardiogram): ‘data’ removed for clarification. The 
investigators are not expected to input data into the dECG, the data will be transferred directly. For the variables to be reported, RR was removed and HR and QTcB were added in order to align the text with the data to be collected at the site.  
17 Section 4.3.6 (Clinical Laboratory Tests): the following tests were added to the additional 
laboratory assessments: adiponectin, lipi[INVESTIGATOR_1800], ELF™, and CK18. Only adiponectin is an additional test, all other tests were included in the previous version of the protocol and have been added here for clarity. Adiponectin is an important lipid parameter for NASH.  
18 Table 5 (Screening Schedule of Procedures): an additional check of eligibility criteria was 
added at V2.  
19 Table 6 (MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of Procedures):  
(a) Requirement for height measurement at D133 removed.  
(b) IP accountability assessment added.  
(c) The term ‘future samples for testing’ removed from lipi[INVESTIGATOR_1800], CK18, and Elf™ 
assessments.  
(d) Serum lipid profile changed to lipid profile.  
20 Table 7 (MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures):  
(a) Requirement for height measurement at D133 removed.  
(b) IP accountability assessment added.  
(c) The term ‘future samples for testing’ removed from lipi[INVESTIGATOR_1800], CK18, and Elf™ 
assessments.  
(d) Changes made to footnote ‘h’ to make BP collection consistent with main body.  
(e) Serum lipid profile changed to lipid profile.  
21 Table 8 (Schedule of Follow-up Procedures):  
(a) Requirement for height measurement removed.  
(b) Serum lipid profile changed to lipid profile.  
(c) IP accountability assessment added.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  95 of 117  Template  18.0   
  
22 Section [IP_ADDRESS] (Additional Analyses of the Efficacy Endpoint): the ANCOVA analysis 
was removed as this analysis is already discussed in Section [IP_ADDRESS].  
23 Appendix B (Adverse Event Definitions and Additional Safety Information): updated to 
reflect operational changes affecting AE reporting.  
 
9.[ADDRESS_824533] been reflected in 
the Protocol Synopsis.  
 
The principal reason for this amendment was to  incorporate feedback from the US FDA to 
improve safety monitoring.  
 
Changes, made in response to US FDA guida nce, are considered substantial and are as 
follows:  
1 Section 4.1.3 (Exclusion Criteria): new exclusion criterion 9 added: ‘Physician-diagnosed 
diabetic subjects with clinically significant ga stroparesis (as judged by [CONTACT_093]) or 
those treated for gastroparesis within 6 months prior to screening’.  
2 Section 4.1.3 (Exclusion Criteria): exclusion criterion 25 (f) changed from 
‘Platelets < 100 × 109/L’ to ‘Platelets < 140-150,000/mm3’. 
3 Table 5 (Screening Schedule of Procedures): an extra visit was added to screening to 
accommodate ABPM (and corresponding footnote) at -10 days ± 3 days.  
4 Table 7 (MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures):  
(a) Six additional visits at Days 51, 52, 65, 66, 79, and 80 added at 24 and 48 hours after 
uptitration to 400, 500 and 600 μg, respectively.  
(b) Postural BP specified at Visits 9 (Day 51), 10 (Day 52), 12 (Day 65), 13 (Day 66), 15 
(Day 79) and 16 (Day 80) with accompanying explanatory footnote.  
(c) ABPM added to Visits 8 (Day 50), 11 (Day 64), 14 (Day 78), and 20 (Day 133).  
(d) Extra sampling was added for plasma glucose, insulin, glucagon, c-peptide, and 
GLP-1 at Visits 8 (Day 50), 9 (Day 51) , 10 (Day 52), 11 (Day 64), 12 (Day 65), 13 
(Day 66), 15 (Day 79), and 16 (Day 80).  
5 Section [IP_ADDRESS] (Vital Signs): clarification and new text added to allow for postural BP 
and ABPM measures at time points specified in Table 7. Section also added to provide details regarding training for the application and wearing of the ABPM device.  
6 Section [IP_ADDRESS] (Unblinding for Interim Analysis Purposes): clarification added that the 
sponsor’s core cross-functional safety team have the capacity to introduce an earlier,  
ad-hoc review of unblinded safety data by [CONTACT_619977].  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824534] additional visits, however, the overall time period of the study was not changed.  
 
Additional changes to the protocol consider ed to be substantial are summarized below:  
 
7 Section 1.6 (Benefit-risk and Ethical Assessment): section updated to align with most 
recent edition of the IB.  
8 Section 2.1 (Primary Objectives and Associated Endpoints): clarifications made to 
primary endpoint wording. Changes made to allow to allow standard reporting on clinicaltrials.gov. All other safety endpoints will be reviewed and detailed in the statistical 
analysis plan.  
9 Section 2.1.1 (Secondary Objectives and Associated Endpoints): clarifications made to 
the other related imaging parameters sec ondary objective and endpoint wording. PDFF 
deleted from MRI, CCI  
10 Section 3.1.1 (Overview) and Section 4.8.6 (Interim Analysis): ‘interim analysis of safety 
data’/’interim safety analysis’/‘safety inter im analysis’ was considered too restrictive, 
therefore, ‘safety data’/‘safety’ was remove d. The interim analysis will be described in 
the interim analysis unblinding plan.  
11 Section [IP_ADDRESS] (Tolerability): addition of instruc tions for investigators to monitor subjects 
with vomiting for signs of hypovolemia and inst ructions regarding hydration for subjects 
with impaired renal function.  
12 Section [IP_ADDRESS] (Hypoglycemia): text clarified to confirm glucose reading and 
hypoglycemic events will be reviewed and managed by [CONTACT_619978] T2DM.  
13 Table 5 (Screening Schedule of Procedures):  
(a) MRI (including MRI-PDFF) and fibroscan moved to new Visit 2 at -10 days to 
maintain the timeframe between these procedures and randomization.  
(b) Footnote added to confirm historical MRI (including MRI-PDFF)/fibroscan 
assessments can be used for screening procedures.  
14 Table 6 (MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of Procedures):  
(a) dECG and vital sign measures on Days 50, 64, and [ADDRESS_824535] 
burden.  
(b) Footnote to clarify dosing added: Subjects are required to be dosed at the clinic for 
the [ADDRESS_824536] 8 hours overnight prior to Visits 3 (Day 1), 10 (Day 78) and 14 (Day 133); subjects are permitted to drink water during this period 
of fasting. On days where subjects attend the clinic in a fasted state, blood and urine 
samples should be obtained prior to administration of investigational product.  
(c) On Visit 20 (Day 133), the 12-hour pharmacokinetic sampling time point was 
changed to [ADDRESS_824537].  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  97 of 117  Template  18.0   
  
15 Table 7 (MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures):  
(a) Footnote to clarify dosing added: Subjects are required to be dosed at the clinic for 
the [ADDRESS_824538] 8 hours overnight prior to Visits 3 (Day 1), 14 (Day 78) and 20 (Day 133); subjects are permitted to drink water during this period 
of fasting. On days where subjects attend the clinic in a fasted state, blood and urine 
samples should be obtained prior to administration of investigational product. Subjects are required to visit the clinic on two subsequent days following up-titration to the 400, 500 and 600 μg dose for safety monitoring; subjects may travel to the site 
for daily visits during this time or alternatively should be given the option to stay 
overnight locally if this is more convenient.  
(b) To monitor subject safety, extra sampling was added for serum chemistry at Visits 8 
(Day 50), 9 (Day 51), 10 (Day 52), 11 (Day 64), 12 (Day 65), 13 (Day 66), 15  
(Day 79), and 16 (Day 80).  
(c) On Visit 20 (Day 133), the 12-hour pharmacokinetic sampling time point was 
changed to [ADDRESS_824539].  
16 
 
 
 
17 
 
18 Section 4.3.12 (Estimate of Volume of Blood to be Collected): total blood volumes were 
updated to reflect additional sampling, approximately 389.4 mL, plus an optional 81.4 mL for the MEDI0382 300 μg/matched placebo group and 480.4 mL, plus an optional  
81.4 mL for the MEDI0382 600 μg/matched placebo group.  CCI 
CCI 
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  98 of 117  Template  18.0   
  
Changes to the protocol considered to be non-substantial are summarized below:  
 
[ADDRESS_824540] organizational changes Covance was removed from the title page.  
20 Section 4.1.2 (Inclusion Criteria 6): Added clarification that the MRI assessment should 
be PDFF, and that an historical MRI-PDFF can be used for the screening hepatic steatosis 
or liver fat assessment.  
21 Table 5 (Screening Schedule of Procedures), Table 7 (MEDI0382/Matched Placebo 
600 μg Treatment Period Schedule of Procedures): AE and concomitant medication 
monitoring included in the extra visits during this amendment.  
22 Table 6 (MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of Procedures): 
NIS4 sample removed from Week 2, as this was incorrectly included in the original protocol.  
23 Table 6 (MEDI0382/Matched Placebo 300 μg Treatment Period Schedule of Procedures) 
and Table 7 (MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of 
Procedures): for clarity ‘dispense glucose meter’ added with accompanying footnote.  
24 Table 7 (MEDI0382/Matched Placebo 600 μg Treatment Period Schedule of Procedures): 
footnote ‘g’, regarding vital signs, which was missing from the original protocol was added.  
25 Table 8 (Schedule of Follow-up Procedures):  
(a) footnote ‘a’ deleted from ADA, this was incorrectly included in the original protocol.  
(b) Clarification added to new footnote ‘a’ to confirm consecutive measurements are for 
BP only.  
26 Section [IP_ADDRESS] (Weight, Height, BMI, Waist and Hip Circumference): clarification to 
confirm height recorded at screening will be used for eligibility assessment, and height 
recorded at Visit 3 (Day 1) will be used for subsequent BMI calculations.  
27 Section [IP_ADDRESS] (Magnetic Resonance Imaging (including MRI-PDFF): CCI  
Added clarification that subjects with 
an MRI performed within 60 days of screening do not need to repeat this assessment at Visit 2 (Day -10).  
28 Section [IP_ADDRESS] (Fibroscan): added clarification that subjects with a fibroscan performed 
within [ADDRESS_824541] a fibroscan performed at  
Visit 2 (Day -10).  
29 Section [IP_ADDRESS] (Dose Preparation Steps): clarification added Table 10 (MEDI0382 and 
Placebo Dose Preparation).  
30 Section 4.5.4 (Storage): clarification added to confirm storage conditions for transit to and 
storage at the subject’s home.  
31 Section 4.7.1 (Permitted Concomitant Medica tions): screening biopsy deleted as no 
screening biopsy will be taken in this study; historical biopsy changed to baseline biopsy for consistency.  
32 Appendix E (Genetic Research): clarification that sample will only be taken on Visit 3 
(Day 1), not at any timepoint as incorrectly included in the original protocol.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  99 of 117  Template  18.0   
  
Appendix A Contraception Guidance  
For females of childbearing potential:  
 
 Females of childbearing potential are defined as those who are not surgically sterile (ie, 
surgical sterilization includes bilateral tubal ligation, bilateral oophorectomy, or 
hysterectomy) or those who are not prem enarchal or postmenopausal defined as  
[ADDRESS_824542] an elevated follicle-stimulating hormone [FSH] central la boratory level > 40 mIU/mL). FSH testing 
will be conducted at the screening visit to confirm postmenopausal status).  
 A highly effective method of contraception is defined as one that results in a low failure 
rate (ie, less than 1% per year) when used consistently and correctly. The acceptable 
methods of contraception are described in Table A1.  
 Female subjects must refrain from egg ce ll donation and breastfeeding while on study and 
for [ADDRESS_824543].  
 
 
Table A1 Highly Effective Methods of Contraception  
 
Barrier  Methods  Hormonal  Methods  
• Copper T intrauterine device  
• Levonorgestrel-releasing intrauterine system or 
implant; eg, Mirena®) a • Implants  
• Hormone shot or injection  
• Combined  pi[INVESTIGATOR_4382] 
• Minipi[INVESTIGATOR_4382]  
• Patch  
a This is also considered a hormonal method.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824544] a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (e.g. an abnormal laboratory finding), symptom (for example nausea, chest pain), or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.  
The term AE is used to include both serious and non-serious AEs and can include a 
deterioration of a pre-existing medical occurrence. An AE may occur at any time, including 
run-in or washout periods, even if no Study treatment has been administered.  
 
B 2 Definitions of Serious Adverse Event  
A serious adverse event is an AE occurring during any study phase (i.e., run-in, treatment, 
washout, follow-up), that fulfils one or more of the following criteria:  
 
 Results in death  
 Is immediately life-threatening  
 Requires in-subject hospi[INVESTIGATOR_15574]  
 Results in persistent or significant disability or incapacity.  
 Is a congenital abnormality or birth defect  
 Is an important medical event that may jeopardise the subject or may require medical 
treatment to prevent one of the outcomes listed above.  
B 3 Life Threatening  
‘Life-threatening’ means that the subject was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the subject’s death. ‘Life-threatening’ does not mean that had an AE occurred in a more severe 
form it might have caused death (e.g., hepatitis that resolved without hepatic failure).  
 
B 4 Hospi[INVESTIGATOR_280843] a serious AE, although the reasons 
for it may be (e.g., bronchospasm, laryngeal oedema). Hospi[INVESTIGATOR_2144]/or surgical operations planned before or during a study are not considered AEs if the illness or disease existed before the subject was enrolled in the study, provided that it did not deteriorate in an 
unexpected way during the study.  
 
B 5 Important Medical Event or Medical Treatment  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824545] drug does not mean that it is an important medical event; medical 
judgement must be used.  
 
 Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatment  
 Hepatotoxicity caused by [CONTACT_76475] (acetaminophen) overdose requiring treatment with 
N-acetylcysteine  
 Intensive treatment in an emergency room or at home for allergic bronchospasm  
 Blood dyscrasias (e.g., neutropenia or anaemia requiring blood transfusion, etc.) or 
convulsions that do not result in hospi[INVESTIGATOR_11956]  
 Development of drug dependency or drug abuse  
B 6 Intensity Rating Scale:  
1 mild (awareness of sign or symptom, but easily tolerated)  
2 moderate (discomfort sufficient to cause interference with normal activities)  
3 severe (incapacitating, with inability to perform normal activities)  
B 7 A Guide to Interpreting the Causality Question  
When making an assessment of causality consider the following factors when deciding if there 
is a ‘reasonable possibility’ that an AE may have been caused by [CONTACT_33641].  
 
 Time Course. Exposure to suspect drug. Has the subject actually received the suspect 
drug? Did the AE occur in a reasonable temporal relationship to the administration of the suspect drug?  
 Consistency with known drug profile. Was the AE consistent with the previous 
knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same 
pharmacological class? Or could the AE be anticipated from its pharmacological properties?  
 De-challenge experience. Did the AE resolve or improve on stoppi[INVESTIGATOR_122570]?  
 No alternative cause. The AE cannot be reasonably explained by [CONTACT_539174], other drugs, other host or environmental factors.  
 Re-challenge experience. Did the AE reoccur if the suspected drug was reintroduced after 
having been stopped? [COMPANY_008] would not  normally recommend or support a re- 
challenge.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  102 of 117  Template  18.0   
  
 Laboratory tests. A specific laboratory investigation (if performed) has confirmed the 
relationship.  
 
In difficult cases, other factors could be considered such as:  
 
 Is this a recognized feature of overdose of the drug?  
 Is there a known mechanism?  
 
Causality of ‘related’ is made if following a revi ew of the relevant data, there is evidence for a 
‘reasonable possibility’ of a causal relationship for the individual case. The expression 
‘reasonable possibility’ of a causal relationship is meant to convey, in general, that there are facts (evidence) or arguments to suggest a causal relationship.  
 
The causality assessment is performed based on the available data including enough 
information to make an informed judgment. With limited or insufficient information in the case, it is likely that the event(s) will be assessed as ‘not related’.  
Causal relationship in cases where the disease under study has deteriorated due to lack of 
effect should be classified as no reasonable possibility.  
 
B 8 Medication Error  
For the purposes of this clinical study a medication error is an unintended failure or mistake in 
the treatment process for an [COMPANY_008] study drug that either causes harm to the participant 
or has the potential to cause harm to the participant.  
 
A medication error is not lack of efficacy of the drug, but rather a human or process related 
failure while the drug is in control of the study site staff or participant.  
 
Medication error includes situations where an error.  
 
 occurred  
 was identified and intercepted before the participant received the drug  
 did not occur, but circumstances were recognize that could have led to an error  
 
 
Examples of events to be reported in clinical studies as medication errors:  
 
 Drug name [CONTACT_2976]  
 Dispensing error e.g. medication prepared incorrectly, even if it was not actually given to 
the participant  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  103 of 117  Template  18.0   
  
 Drug not administered as indicated, for example, wrong route or wrong site of 
administration  
 Drug not taken as indicated e.g. tablet dissolved in water when it should be taken as a 
solid tablet  
 Drug not stored as instructed e.g. kept in the fridge when it should be at room temperature  
 Wrong participant received the medication (excluding IVRS/IWRS errors)  
 Wrong drug administered to participant (excluding IVRS/IWRS errors)  
 
 
Examples of events that do not require reporting as medication errors in clinical studies:  
 
 Errors related to or resulting from IVRS/IWRS - including those which lead to one of the 
above listed events that would otherwise have been a medication error  
 Participant accidentally missed drug dose(s) e.g. forgot to take medication  
 Accidental overdose (will be captured as an overdose)  
 Participant failed to return unused medication or empty packaging  
 Errors related to background and rescue medication, or standard of care medication in 
open label studies, even if an AZ product  
Medication errors are not regarded as AEs but AEs may occur as a consequence of the 
medication error.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  104 of 117  Template  18.0   
  
Appendix C National Institute of Allergy and Infectious Diseases and 
Food Allergy and Anaphylaxis Network Guidance for Anaphylaxis Diagnosis  
Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson FN Jr, Bock SA, Branum A, et al. 
Second symposium on the definition and management of anaphylaxis: Summary report -- Second National Institute of Allergy and Infec tious Disease/Food Allergy and Anaphylaxis 
Network symposium. J Allergy Clin Immunol. 2006; 117:391-7.  
National Institute of Allergy and Infectious Diseases (NIAID) and Food Allergy and 
Anaphylaxis Network (FAAN) define anaphylaxis as  a serious allergic reaction that is rapid in 
onset and may cause death. They recognize 3 categories of anaphylaxis, with criteria designated to capture from 80% of cases (category 1) to > 95% of all cases of anaphylaxis (for 
all 3 categories).  
 
1 Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula) AND AT LEAST ONE OF THE FOLLOWING  
(a) Respi[INVESTIGATOR_7798] (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak 
expi[INVESTIGATOR_10229] (PEF), hypoxemia)  
(b) Reduced blood pressure (BP) or associated symptoms of end-organ dysfunction (eg, 
hypotonia [collapse], syncope, incontinence)  
2 Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely allergen for that 
patient (minutes to several hours):  
(a) Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen 
lips-tongue-uvula)  
(b) Respi[INVESTIGATOR_7798] (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia)  
(c) Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, 
incontinence)  
(d) Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting)  
3 Reduced BP after exposure to known allergen for that patient (minutes to several hours):  
(a) Infants and children: low systolic BP (age specific) or greater than 30% decrease in 
systolic BP  
(b) Adults: systolic BP of less than 90 mmHg or greater than 30% decrease from that 
person’s baseline  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  105 of 117  Template  18.0   
  
Appendix D Actions Required in Cases of Increases in Liver Biochemistry 
and Evaluation of Hy’s Law  
D 1 Introduction  
This appendix describes the process to be followed in order to identify and appropriately 
report potential Hy’s Law (PHL) cases and Hy’s Law (HL) cases. It is not intended to be a 
comprehensive guide to the management of elevated liver biochemistries.  
 
During the course of the study, the investigator will remain vigilant for increases in liver 
biochemistry. The investigator is responsible for determining whether a subject meets potential Hy’s Law criteria at any point during the study.  
 
All sources of laboratory data are appropriate for the determination of PHL and HL events; 
this includes samples taken at scheduled study vi sits and other visits including central and all 
local laboratory evaluations even if collected outside of the study visits; for example, PHL 
criteria could be met by [CONTACT_96724] a central laboratory and/or elevated TBL from 
a local laboratory.  
The investigator will also review AE data (for example, for AEs that may indicate elevations 
in liver biochemistry) for possible potential Hy’s Law events.  
 
The investigator participates, together with MedImmune clinical project representatives, in 
review and assessment of cases meeting potential Hy’s Law criteria to agree whether Hy’s Law criteria are met. Hy’s Law criteria are met if there is no alternative explanation for the elevations in liver biochemistry other than drug-induced liver injury (DILI) caused by [CONTACT_7198].  
The investigator is responsible for recording data pertaining to potential Hy’s Law/Hy’s Law 
cases and for reporting AEs and SAEs according to the outcome of the review and assessment in line with standard safety reporting processes.  
 
D 2 Definitions  
D 2.1 Potential Hy’s Law  
AST or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN at any point during the study 
following the start of investigational product irrespective of an increase in alkaline 
phosphatase (ALP).  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  106 of 117  Template  18.0   
  
D 2.2 Hy’s Law  
AST or ALT ≥ 3 × ULN together with TBL ≥ 2 × ULN, where no other reason, other than 
the investigational product, can be found to explain the combination of increases; eg, elevated ALP indicating cholestasis, viral hepatitis, or another drug.  
 
For potential Hy’s Law and Hy’s Law, the elevation in transaminases must precede or be 
coincident with (ie, on the same day) the elevation in TBL, but there is no specified timeframe 
within which the elevations in transaminases and TBL must occur.  
 
D 3 Identification of Potential Hy’s Law Cases  
In order to identify cases of potential Hy’s Law, it is important to perform a comprehensive 
review of laboratory data for any subject who meets any of the following identification criteria in isolation or in combination:  
 
 ALT ≥ 3 × ULN  
 AST ≥ 3 × ULN  
 TBL ≥ 2 × ULN  
 
When a subject meets any of the identification criteria, in isolation or in combination, the 
central laboratory will immediately send an alert to  the investigator (also sent to sponsor study 
representative).  
 
The investigator will also remain vigilant for any local laboratory reports where the 
identification criteria are met, where th is is the case the investigator will:  
 
 Notify the sponsor study representative  
 Request a repeat of the test (new blood draw) by [CONTACT_591354]  
 Complete the appropriate unscheduled laboratory case report form (CRF) module(s) with 
the original local laboratory test result  
 
When the identification criteria are met from central or local laboratory results the investigator 
will without delay:  
 
  Determine whether the subject meets potential Hy’s Law criteria (see Section D 2) by 
[CONTACT_62685] (including both central and local 
laboratory results)  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  107 of 117  Template  18.0   
  
D 4 Follow-up  
D 4.1 Potential Hy’s Law Criteria Not Met  
If the subject does not meet potential Hy’s Law criteria the investigator will:  
 
 Inform the study representative that the subject has not met potential Hy’s Law criteria.  
 Perform follow-up on subsequent laboratory results according to the guidance provided in 
the study protocol.  
 
D 4.2 Potential Hy’s Law Criteria Met  
If the subject does meet potential Hy’s Law criteria the investigator will:  
 
 Notify the sponsor study representative who will then inform the study team  
 Within 1 day of potential Hy’s Law criteria being met (Appendix D 6), the investigator 
will report the case as an SAE of Potential Hy ’s Law; serious criteria ‘Important medical 
event’ and causality assessment ‘yes/related’ according to clinical study protocol process for SAE reporting  
 
The medical monitor contacts the investigator, to provide guidance, discuss and agree on an 
approach for the study subjects’ follow-up (including any further laboratory testing) and the continuous review of data.  
 
  Subsequent to this contact  [CONTACT_280886]:  
 Monitor the subject until liver biochemistr y parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated. Complete follow-up SAE Form as required.  
 Investigate the etiology of the event and perform diagnostic investigations as 
discussed with the medical monitor. This includes deciding which the tests available 
in the Hy’s Law lab kit should be used.  
 Complete the relevant CRF Modules as information becomes available  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  108 of 117  Template  18.0   
  
D 5 Review and Assessment of Potential Hy’s Law Cases  
The instructions in this section should be followed for all cases where potential Hy’s Law 
criteria are met.  
 
As soon as possible after the biochemistry abnormality was initially detected, the medical 
monitor will contact [CONTACT_619979]’s Law criteria other than DILI 
caused by [CONTACT_7198], to ensure timely analysis and reporting to health 
authorities per local requirements from the date potential Hy’s Law criteria were met. The medical monitor and Global Safety Physician w ill also be involved in this review together 
with other subject matter experts as appropriate.  
According to the outcome of the review and assessment, the investigator will follow the 
instructions below.  
 
Where there is an agreed alternative explanation for the ALT or AST and TBL elevations, 
a determination of whether the alternative explanation is an AE will be made and 
subsequently whether the AE meets the criteria for an SAE:  
 
 If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate CRF  
 If the alternative explanation is an AE/SAE, update the previously submitted potential 
Hy’s Law SAE and AE CRFs accordingly with the new information (reassessing event 
term; causality and seriousness criteria) fo llowing the sponsor’s standard processes  
 
If it is agreed that there is no explanation that would explain the ALT or AST and TBL 
elevations other than the investigational product:  
 
 Send the updated SAE (report term ‘Hy’s Law’) according to the sponsor’s standard 
processes.  
 The ‘Medically Important’ serious criterion should be used if no other serious criteria 
apply  
 As there is no alternative explanation for the Hy’s Law case, a causality assessment 
of ‘related’ should be assigned  
 
If, there is an unavoidable delay of over 15 calendar days in obtaining the information 
necessary to assess whether or not the case meets the criteria for Hy’s Law, then it is assumed that there is no alternative explanation until such time as an informed decision can be made:  
 
 Provide any further update to the previously submitted SAE of Potential Hy’s Law (report 
term now ‘Hy’s Law case’),  ensuring causality assessment are related to the  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824546] and seriousness criteria is medically important, according to the 
clinical study protocol process for SAE reporting  
 Continue follow-up and review according to agreed plan. Once the necessary 
supplementary information is obtained, repeat the review and assessment to determine 
whether Hy’s Law criteria are still met. Upda te the previously submitted potential Hy’s 
Law SAE report following clinical study protocol process for SAE reporting, according to 
the outcome of the review and amend the reported term if an alternative explanation for the liver biochemistry elevations is determined  
 
D 6 Actions Required for Repeat Epi[INVESTIGATOR_33099]’s Law  
This section is applicable when a subject meets potential Hy’s Law criteria on study treatment 
and has already met potential Hy’s Law criteria at a previous on study treatment visit.  
 
The requirement to conduct follow-up, review, and assessment of a repeat occurrence(s) of 
potential Hy’s Law is based on the nature of the alternative cause identified for the previous 
occurrence.  
 
The investigator should determine the cause for the previous occurrence of potential Hy’s Law 
criteria being met and answer the following question:  
 
 Was the alternative cause for the previous occurrence of potential Hy’s Law criteria being 
met found to be the disease under study eg, chronic or progressing malignant disease, 
severe infection, or liver disease.  
 
If No: follow the process described in Section D 4.2 , for reporting potential Hy’s Law as an 
SAE.  
 
If Yes: Determine if there has been a significant change in the subject’s condition compared 
with when potential Hy’s Law criteria were previously met:  
 
 If there is no significant change no action is required  
 If there is a significant change follow the process described in Section D 4.2 , for reporting 
potential Hy’s Law as an SAE  
 
A ‘significant’ change in the subject’s condition refers to a clinically relevant change in any of 
the individual liver biochemistry parameters (ALT, AST, or TBL) in isolation or in combination, or a clinically relevant change in associated symptoms. The determination of 
whether there has been a significant change will be at the discretion of the investigator; this 
may be in consultation with the medical monitor if there is any uncertainty.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824547] results need to be recorded.  
 
Hy’s Law lab kit for central laboratories  
 
Additional standard chemistry and coagulation 
tests GGT 
LDH  
Prothrombin time  
INR 
Viral hepatitis  IgM anti-HAV 
IgM and IgG anti-HBc  
HBsAg 
HBV DNA  
IgG anti-HCV 
HCV RNA*  
IgM anti-HEV  
HEV  RNA  
Other viral infections  IgM & IgG anti-CMV 
IgM & IgG anti-HSV  
IgM & IgG anti-EBV  
Alcoholic  hepatitis  Carbohydrate deficient transferrin (CD-transferrin)  
Autoimmune  hepatitis  Antinuclear antibody (ANA)  
Anti-Liver/Kidney Microsomal Ab (Anti-LKM) 
Anti-Smooth Muscle Ab (ASMA)  
Metabolic  diseases  alpha-1-antitrypsin 
Ceruloplasmin 
Iron 
Ferritin 
Transferrin  
Transferrin  saturation  
*HCV RNA is only tested when IgG anti-HCV is positive or inconclusive  
 
REFERENCES  
Aithal et al 2011, Clinical Pharmacology and Therapeutics 89(6):806-815.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  111 of 117  Template  18.0   
  
FDA Guidance for Industry (issued July 2009) 'Drug-induced liver injury: Premarketing 
clinical evaluation'  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824548] fulfil all of the inclusion criteria described 
in the main body of the Clinical Study Protocol and: 
 
 Provide informed consent for the genetic sampling and analyses.  
 
Exclusion criteria  
Exclusion from this genetic research may be for any of the exclusion criteria specified in the 
main study or any of the following:  
 
Discontinuation of subjects from this genetic research  
Specific reasons for discontinuing a subj ect from this genetic research are:  
 
Withdrawal of consent for genetic research: S ubjects may withdraw from this genetic research 
at any time, independent of any decision concerning participation in other aspects of the main 
study. Voluntary discontinuation will not prejudice further treatment. Procedures for 
discontinuation are outlined in Section 4.1.7 of the protocol.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  113 of 117  Template  18.0   
  
Collection of samples for genetic research  
The blood sample for genetic research will be obtained from the subjects at Visit 3 (Day 1). 
Only one sample should be collected per subject for genetics during the study. Samples will 
be collected, labelled, stored and shipped as detailed in the Laboratory Manual.  
 
Coding and storage of DNA samples  
The processes adopted for the coding and storage of samples for genetic analysis are 
important to maintain subject confidentiality. Samples will be stored for a maximum of  
[ADDRESS_824549] visit, after which they will be destroyed. DNA is a 
finite resource that is used up during analyses . Samples will be stored and used until no further 
analyses are possible or the maximum storage time has been reached.  
 
An additional second code will be assigned to the blood either before or at the time of DNA 
extraction replacing the information on the sample tube. Thereafter, the sample will be 
identifiable by [CONTACT_33160], unique number only. This number is used to identify the sample and corresponding data at the MedImmune genetics laboratories, or at the designated 
organization. No personal details identifying the individual will be available to any person 
(MedImmune employee or designated organizations working with the DNA).  
 
The link between the subject enrolment/randomization code and the second number will be 
maintained and stored in a secure environment, with restricted access at MedImmune or designated organizations. The link will be used to identify the relevant DNA samples for analysis, facilitate correlation of genotypic results with clinical data, allow regulatory audit and to trace samples for destruction in the case of withdrawal of consent.  
 
Ethical and Regulatory Requirements  
The principles for ethical and regulatory requi rements for the study, including this genetics 
research component, are outlined in Section [ADDRESS_824550] udy center. The Principal Investigator(s) is 
responsible for ensuring that consent is given freely and that the subject understands that they may freely discontinue from the genetic  aspect of the study at any time.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824551]’s identity and also have access to his or her genetic data. Also, Regulatory authorities may require access to the relevant files, though the subject’s medical information and the genetic files would remain physically separate.  
Data management  
Any genotype data generated in this study will be stored at a secure system at MedImmune 
and/or designated organizations to analyze the samples.  
 
The results from this genetic research may be reported in a separate report from the CSR or 
published in scientific journals.  
 
MedImmune and its designated organizations may share summary results (such as genetic 
differences from groups of individuals with a di sease) from this genetic research with other 
researchers, such as Hospi[INVESTIGATOR_600], Academic Orga nization or Health Insurance Companies. This 
can be done by [CONTACT_103472], where they can be combined with 
the results of similar studies to learn even more  about health and disease. The researchers can 
only use this information for health related research purposes. Researchers may see summary results, but they will not be able to see individual subject data or any personal identifiers.  
Some or all of the clinical datasets from the main study may be merged with the genetic data 
in a suitable secure environment separate from the clinical database.  
 
Statistical Methods and Determination of Sample Size  
The number of subjects that will agree to participate in the genetic research is unknown. It is 
therefore not possible to establish whether sufficient data will be collected to allow a formal 
statistical evaluation or whether only descriptive statistics will be generated. A statistical 
analysis plan will be prepared where appropriate.  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824552] (AUDIT)  
 
Alcohol Use Disorders Identification Test - Self Report Version - (AUDIT)  
PATIENT: Because alcohol use can affect your heal th and can interfere with certain medications and 
treatments, it is important that we ask some ques tions about your use of alcohol. Your answers will 
remain confidential so  please be honest.  
Place an X in [ADDRESS_824553] a drink 
containing alcohol?   
  
  
  
  
 
Never  Monthly or 
less 2-[ADDRESS_824554] on a typi[INVESTIGATOR_33614]?
  
  
  
  
  
 
[ADDRESS_824555] six or 
more drinks on one occasion?   
  
  
  
  
 
Never  Less than 
monthly  Monthly  Weekly  Daily or 
almost daily  
 
[ADDRESS_824556] you found that you were not able 
to stop drinking once you had started?   
  
  
  
  
 
Never  Less than 
monthly  Monthly  Weekly  Daily or 
almost daily  
 
[ADDRESS_824557] you failed to do what was 
normally expected of you because of 
drinking?   
  
  
  
  
 
Never  Less than 
monthly  Monthly  Weekly  Daily or 
almost daily  
 
[ADDRESS_824558] drink in the morning to get yourself going after a 
heavy drinking session?
  
  
  
  
  
 
Never  Less than 
monthly  Monthly  Weekly  Daily or 
almost daily  
 
[ADDRESS_824559] you had a feeling of guilt or 
remorse after drinking?   
  
  
  
  
 
Never  Less than 
monthly  Monthly  Weekly  Daily or 
almost daily  
 
[ADDRESS_824560] you been unable to remember what happened the night before 
because of your drinking?
  
  
  
  
  
 
Never  Less than 
monthly  Monthly  Weekly  Daily or 
almost daily  
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824561] - Self Report Version - (AUDIT)  
PATIENT: Because alcohol use can affect your heal th and can interfere with certain medications and 
treatments, it is important that we ask some ques tions about your use of alcohol. Your answers will 
remain confidential so  please be honest.  
Place an X in [ADDRESS_824562] you or someone else been 
injured because of your drinking?   
   
   
 
No  Yes, but not 
in the last 
year  Yes, during 
the last year  
 
10  Has a relative, friend, doctor, or 
other health care worker been concerned about your drinking or suggested you cut down?
  
   
   
 
No  Yes, but not 
in the last 
year  Yes, during 
the last year  
 
Total    
MedImmune  Protocol D5671C00002 Amendment 6  
MEDI0382  
27Nov2020;  Final  
CONFIDENTIAL AND PROPRIETARY  [ADDRESS_824563] (AUDIT) - Scoring 
instructions  
Scoring the AUDIT questionnaire  
Scores for each question range from [ADDRESS_824564] response for each question (eg,  
never) scoring 0, the second (eg, less than monthly) scoring 1, the third (eg, monthly) scoring 
2, the fourth (eg, weekly) scoring 3, and the last response (eg, daily or almost daily) scoring 4. For questions [ADDRESS_824565] 3 responses, the scoring is 0, 2, and 4 (from left to 
right). A score of [ADDRESS_824566] that was signed 
electronically and this page is the manifestation of the electronic signature  
 
[CONTACT_24558]: d5671c00002-csp-amendment-6  
Document Title:  D5671C00002 Clinical Study Protocol Amendment 6  
Document ID:  Doc ID-004250975  
Version Label:  2.[ADDRESS_824567] APPROVED  
Server Date  
(dd-MMM-yyyy HH:mm ‘UTC’Z)  Signed by  [CONTACT_24557]  
02-Dec-2020 16:03 UTC  [COMPANY_003]  Management Approval  
02-Dec-2020 16:17 UTC  [COMPANY_003]  Content Approval  
03-Dec-2020 13:04 UTC  [COMPANY_003]  Content Approval  
03-Dec-2020 04:56 UTC  [COMPANY_003] [COMPANY_003] Content Approval  
02-Dec-2020 20:15 UTC  [COMPANY_003]  Qualified Person Approval  
Notes: (1) Document details as stored in ANG EL, an [COMPANY_008] document management system.  